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                                      ABSTRACT
Until  the  1990s,  venous  thromboembolism  (VTE)  was  viewed  primarily  as  a 
complication  of  hospitalization  for  major  surgery  or  major  medical  illness.  However 
epidemiologic studies have shown that between one quarter and one half of all clinically 
recognized  symptomatic  VTEs occur  in  individuals  who are  neither  hospitalized  nor 
recovering from a major illness. Evaluations of risk factors in this group of patients help 
to  identify  high-risk  patients  who  could  benefit  from prophylaxis.  In  this  study,  we 
evaluated  such risk  factors  in  patients  referred  for  thrombophilia  risk  screening.  266 
patients with documented deep vein thrombosis were evaluated for thrombophilia risk 
factors. Median age of presentation is 38 years (4-74) and only 4/266 (1.5%) were below 
15 years of age. History of recurrence and family history was present in 38/266 (14.3%) 
and 10/266 (3.8%) of patients, respectively. Male: Female ratio was 1:1.1 (140/126) for 
the whole group. Males were more commonly affected than females in the subgroups 
also, except for patients with cortical  sinus thrombosis, where male: female ratio was 
0.6:1. The presenting features were lower limb deep vein thrombosis in 123/266 (46.2%) 
patients, followed by cortical sinus thrombosis in 92/266 (34.6%), pulmonary embolism 
in 26/266 (9.8%) and Budd Chiari  syndrome was seen in  20/266 (7.5%) of  patients. 
121/266 (45.5%) of patients  were on anticoagulant  therapy at  the time of evaluation. 
Prothrombotic risk factors were present in 163/266 (61.3%) of patients and no risk factors 
were identified in 103/266 (38.7%) of patients. More than one risk factor was seen in 
104/266 (39.1%) of patients. The most common risk factor identified in these patients 
was an elevated factor VIII level- seen in 159/266 (59.7%) of patients. Factor V Leiden 
mutation was seen in 16/203 (7.9%) patients, Prothrombin G20210A mutation in 2/203 
(1.0%)  and  MTHFR Cys677Thr  homozygous  mutations  in  7/203  (3.4%)  of  patients 
evaluated for these parameters. In patients with Budd Chiari syndrome the prevalence of 
Factor  V Leiden mutation  was 13.3%. Protein  C,  S and antithrombin  deficiency was 
present in 7/266 (2.6%), 13/266 (4.8%) and 20/266 (7.5%) respectively.
2
INTRODUCTION
Venous thrombosis, comprising deep vein thrombosis (DVT) and pulmonary embolism 
(PE),  occurs  with  an  incidence  of  approximately  1  per  1,000  annually  in  adult 
populations.1 The  major  outcomes  of  venous  thrombosis  are  death,  recurrence,  post-
thrombotic  syndrome,  and major  bleeding due to  anticoagulation.  Thrombosis  is  also 
associated  with  impaired  quality  of  life,  particularly  when post-thrombotic  syndrome 
develops.2,3 Death occurs within 1 month of an episode in about 6% of those affected with 
DVT and 10% of those with PE.4 The mortality rate for PE has been estimated to be high 
as 30% in studies that included autopsy-based PE diagnosis,5 emphasizing that many PE 
are not recognized clinically before death. Although knowledge of the pathogenesis of 
venous thromboembolism has advanced markedly over recent years, how best we use this 
knowledge to improve outcomes in clinical practice raises important questions. It  has 
become  common  practice  for  individuals  presenting  with  suspected  venous 
thromboembolism  to  be  subjected  to  a  variable  range  of  laboratory  tests  for  the 
identification  of  heritable  and acquired  prothrombotic  states,  or  thrombophilia.  While 
superficially  this  may seem to  be  an  entirely  reasonable  approach,  evidence  that  the 
results of some such investigations should guide clinical management is incomplete. 
Cerebral vein thrombosis (CVT) is a rather uncommon thrombotic disease. However, the 
recent  introduction  of  noninvasive and highly sensitive  diagnostic  techniques  such as 
magnetic  resonance  imaging  (MRI),  magnetic  resonance  angiography  (MRA),  and 
computed tomography angiography (CTA) has modified our knowledge of the spectrum 
of illness associated with CVT.
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This study aims to study the profile of patients diagnosed with deep vein thrombosis in 
CMC, Vellore.
2
REVIEW OF LITERATURE
Introduction
The  clinical  definition  of  thrombosis  is  that  of  the  pathological  presence  of  a  clot 
(thrombus) in a blood vessel or in the heart that causes the obstruction of blood flow 
through the circulatory system.  Depending on the location where thrombus formation 
takes place (i.e. in the venous or arterial part of the vessel tree), thrombotic disease can be 
classified into venous and arterial thrombosis. Both types of thrombosis are considered as 
distinct  disease  states  that  are  characterized  by  different  pathogenic  mechanisms  and 
underlying risk factors.
Venous  thromboembolism  (VTE),  comprising  deep-vein  thrombosis  (DVT)  and 
pulmonary  embolism  (PE),  is  associated  with  substantial  morbidity  and  mortality.  
Detailed estimates of the annual number of VTE events are hard to obtain because VTE 
is difficult to diagnose. This is due to a number of factors; VTE is often clinically silent  
and, in many cases, the first sign of the disease is a sudden fatal PE.5,6
The chronic nature of VTE and its recurrences and complications requires considerable 
healthcare resources for its management. Additionally, morbidity and healthcare costs are 
incurred  from  associated  complications  of  VTE,  such  as  post-thrombotic  syndrome 
(PTS),  which  affects  at  least  one-third  of  DVT  patients7,8,9,10,11,  and  pulmonary 
hypertension (PH), which occurs in 4%–5% of patients following PE12. 
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Pathophysiology
Central to the pathogenesis of both venous and arterial thrombosis is the perturbation of 
the  normal  haemostatic  balance.  In  healthy  individuals,  haemostasis  is  carefully 
controlled by several anticoagulant mechanisms that prevent inappropriate vascular blood 
clotting. Several observations are even in favor of a slight dominance of the anticoagulant 
forces during homeostasis.13 This dynamic equilibrium between pro- and anticoagulant 
factors can be rapidly shifted in favor of coagulation, in case of a physiological need for 
cessation of blood loss. To prevent excessive blood loss, the hemostatic system, which 
includes platelets, endothelial cells, and plasma coagulation proteins, is called into play. 
Immediately after tissue injury, a platelet plug is formed through the processes of platelet 
adhesion and aggregation. Blood coagulation may be considered a mechanism for rapid 
stabilization  of  an  otherwise  unstable  platelet  plug  with  a  fibrin  clot.  A  series  of 
interdependent enzyme-mediated reactions translates the molecular signals that initiate 
blood coagulation into a major biologic event - the formation of the fibrin clot. However, 
this proneness towards clot formation implies a risk to develop thrombosis. 
In 1884, Rudolph Virchow, the German pioneer in the field of haemostasis, postulated 
that three major causes contribute to thrombus formation (Virchow’s triad) (fig: 1)  
• Vascular endothelial damage
• Stasis of blood flow
• Hypercoagulability of blood. 
                                        Figure-1
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Vascular endothelium
The  normal,  unperturbed  endothelium  represents  a  dynamic  interface  between  the 
flowing blood and the vessel wall. The endothelium regulates the fluid state of blood, 
vascular tone, inflammatory processes, vascular permeability, and vascular fragility. In its 
basal state, the endothelium presents a non-thrombogenic surface to the circulation by 
inhibiting platelet aggregation, preventing the activation and propagation of coagulation, 
and enhancing fibrinolysis14. These activities are accomplished by both passive and active 
processes. 
Inhibition of platelets
When in close proximity to endothelial cells, platelets become unresponsive to agonists. 
This inhibition of platelet aggregation is accomplished by the secretion of prostaglandin 
I2 (PGI2), or prostacyclin, and nitric oxide (NO), and by the surface expression of an ecto-
ADPase identified as CD39.15 Prostacyclin is synthesized mainly by vascular endothelial 
and smooth muscle cells as a product of arachidonic acid metabolism. It inhibits platelet 
activation, secretion, and aggregation and monocyte interactions with endothelial cells. It 
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also causes vascular smooth muscle cell relaxation.  NO similarly has a wide range of 
functions, including the inhibition of platelet adhesion, activation, and aggregation. Most 
of the NO released from endothelial cells is elaborated abluminally, where it acts on the 
smooth muscle cell to cause vasodilation. Some NO also may enter the lumen, however, 
and  from there  diffuse  into  platelets.  Prostacyclin  and  NO can  act  synergistically  to 
reverse platelet aggregation16. The released platelet agonist adenosine diphosphate (ADP) 
can be inactivated by endothelial membrane-associated CD39 by metabolism of ATP and 
ADP to cyclic adenosine monophosphate (cAMP). This eliminates platelet recruitment 
and  returns  the  platelets  to  their  resting  state.  ATP  and  ADP  can  stimulate 
purinoreceptors on endothelial cells, resulting in synthesis and release of PGI2 and NO.17 
Inhibition of coagulation
Four mechanisms may be utilized by endothelial cells to inhibit coagulation.16
(1) Thrombomodulin  on  the  surface  of  endothelial  cells  binds  thrombin.  This 
coupling  inhibits  the  coagulant  properties  of  thrombin  and  also  increases  its 
affinity for protein C, which it cleaves and activates. The activation of protein C 
by the thrombin-thrombomodulin complex is augmented by its binding to the 
endothelial cell protein C receptor. 
(2) Protein S, which is thought to be synthesized primarily by the endothelial cell, 
acts as a cofactor for protein C but also has anticoagulant properties in its own 
right. Independent of the presence of activated protein C, free protein S is able to 
inhibit the prothrombinase and intrinsic tenase complexes and interact directly 
with factors Va and VIIIa.18
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(3) Heparan  sulfate  proteoglycans  are  secreted  onto  the  luminal  surface  of 
endothelial  cells  and into the subendothelium and are capable of binding and 
activating  antithrombin,  thereby  accelerating  the  inactivation  of  several 
procoagulant serine proteases including thrombin, factor Xa, and factor IXa. 
(4) Tissue  factor  pathway  inhibitor  (TFPI)  is  synthesized  in  the  liver  and  in 
endothelial cells and has been shown to be localized to apical granules of the 
endothelial cell. The tissue factor-factor VIIa-factor Xa complex is inhibited by 
TFPI. 
Blood Stasis
Venous stasis represents an important pathogenic factor in the development of PE. The 
role of venous stasis has been investigated in patients with spinal cord injury and other 
forms of paralysis. These studies show that the majority of venous thrombi originate in 
regions of slow blood flow, e.g., the large venous sinuses of the calf and thigh or in valve 
cusp pockets  or  bifurcations  of  the  venous system.  It  has  been suggested  that  blood 
pooling leads to activation of the coagulation system, thus resulting in a state of local 
hypercoagulability. In addition, possible endothelial damage from distension of the vessel 
walls by the pooling blood leads to further activation of the homeostasis  system. The 
activation products of clotting and fibrinolysis can also induce endothelial damage which, 
in turn, promotes a local state of hypercoagulability. 
Hypercoagulability
The risk of venous thrombosis is increased when the homeostatic balance between pro- 
and anticoagulant forces is shifted in favor of coagulation. When this imbalance is due to 
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an inherited defect, the resulting hypercoagulable state remains a life-long risk factor for 
thrombosis. In contrast, hypercoagulability due to a transient factor should be treated only 
as long as the risk factor is present. In most cases, disturbances in the coagulation cascade 
arise in inherited thrombophilias.19 Since each genetic defect represents an independent 
risk factor for thrombosis, individuals with multiple defects have a significantly increased 
risk of thrombosis.
Risk Factors for Venous Thromboembolism
In  the  last  century,  recognition  that  all  DVT  risk  factors  reflect  these  underlying 
pathophysiologic processes and that VTE does not usually develop in their absence has 
increased.  An understanding of the risk factors for venous thrombosis  is necessary in 
order to maximize the prevention of this disease in high-risk individuals and groups of 
patients. This is because DVT rarely occurs in the absence of risk factors.  These risk 
factors are cumulative in their  effect.  Usually,  more than one risk factor is present in 
patients  with  DVT. In  one  study of  patients  thought  to  have  DVT,  the  incidence  of 
abnormal noninvasive test results was 11% when no major risk factors were present, 24% 
when 1 risk factor was present, 36% when 2 major risk factors were present, 50% when 3 
major risk factors were present and 100% when 4 or more risk factors were present20. 
Risk  factors  convincingly  demonstrated  for  VTE  include  increasing  age,  prolonged 
immobility,  malignancy, major surgery, multiple trauma, prior VTE, and chronic heart 
failure (Table 1)21. However, it  is important to recognize that the predictive values of 
these factors are not equal.
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Table 1: Risk Factors for VTE22
Strong  risk  factors 
(odds ratio>10)
Moderate risk factors 
(odds ratio 2–9)
Weak risk factors 
(odds ratio <2)
Fracture (hip or leg) Malignancy Bed rest >3 days
Hip/ knee replacement Central venous lines/ chemotherapy Immobility due to sitting 
Major general surgery Previous VTE Increasing age
Major trauma Congestive heart/ respiratory failure Laparoscopic surgery 
Spinal cord injury Hormone replacement therapy Obesity
Oral contraceptive therapy Pregnancy/ antepartum
Inherited Thrombophilia Varicose veins
On the basis of identifiable risk factors and potential causes, VTE may be divided into 
secondary, primary, and idiopathic VTE.  The major risk factors for thrombosis include 
endogenous patient  characteristics  such as  obesity  and genetic  factors,  and triggering 
factors  such  as  surgery,  immobility,  or  pregnancy.  Some  of  the  risk  factors  are 
modifiable, while others, like advancing age and genetic predispositions, are not. Venous 
thrombosis  tends  to  occur  due  to  the  additive  effects  of  endogenous,  genetic,  and 
environmental risk factors present simultaneously.  This includes the additive effects of 
environmental risk factors, as illustrated in Fig 2. 22,23
Figure 2 conceptual framework for the 
interaction of risk factors in development of 
venous thrombosis. Intrinsic thrombosis risk is 
defined by the combinations of genetic and 
acquired risk factors, including modulation of 
coagulation activation by known and unknown 
determinants. The intrinsic risk is altered by the 
occurrence of triggering risk factors, which can 
be balanced in appropriate settings by use of 
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Thrombophilia
Approximately 80% to 90% of all causes of thrombosis can now be defined with respect 
to cause. Of these, more than 50% of all patients harbor a congenital or acquired blood 
coagulation protein or platelet defect that caused the thrombotic event. It is obviously of 
major importance to define those individuals harboring such a defect, as this allows: 
(1) Appropriate antithrombotic therapy to decrease risks of recurrence 
(2) Determination of the time the patient should remain on therapy for secondary 
prevention, and 
(3) Testing of family members in those harboring a blood coagulation protein or 
platelet defect that is hereditary.
Thrombophilia is defined as a disorder associated with an increased tendency to venous 
thromboembolism (VTE).24 The term thrombophilia was introduced as aMeSH (Medical 
Subject Headings) term in 1998. Thrombophilia can be acquired or inherited.
Acquired thrombophilia
Major General Surgery
The risk of VTE after major general surgery has been extensively documented. The term 
“major  general  surgery”  is  applied  to  patients  who  undergo  abdominal  or  thoracic 
operations that require general anesthesia lasting > 30 minutes.25,26 Other types of surgery 
associated  with  a  high   risk  of  VTE include  coronary  artery  bypass,27,28 surgery  for 
gynecological  malignancies,29,30 and  major  urological  surgery.24 The  risk  after 
neurosurgery is similar.31
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Major Orthopedic Surgery
Lower  extremity  orthopedic  operations  carry  a  particularly  high  risk.  Without 
prophylaxis,  approximately  half  of  the  patients  undergoing elective  total  hip  or  knee 
replacement develop VTE. However, only about 5% of these patients manifest symptoms 
of VTE.24,32 whereas calf vein thrombi tend to be evenly distributed between the 2 legs in 
patients  recovering  from  hip  replacement,  90%  of  proximal  thrombi  occur  on  the 
operated side.33,34 Patients undergoing arthroscopic knee surgery are at low to moderate 
risk, so VTE prophylaxis is optional.35
Spinal Cord Injury
The overall incidence of DVT within 3 months of paralytic spinal cord injury is 38%; the 
corresponding frequency of PE is < 5%.36 The risk appears greatest during the first 2 
weeks after injury,  and fatal  PE is rare > 3 months after injury.  37,38 The cause of the 
decrease in  clinically  evident  PE after  3 months  is  unknown. However,  a  number  of 
changes associated with chronic paralysis may be involved, including gradual atrophy of 
the leg muscles  and, in many individuals,  the development  of small  caliber  collateral 
veins around organized old venous thrombi that completely obstruct the deep leg veins.
Fracture of the Pelvis, Hip, or Long Bones
Patients with traumatic hip fracture are at high risk for VTE. The problem was further 
emphasized in 1959 when the first controlled trial of anticoagulant prophylaxis after hip 
fracture showed a reduction from 10% to 0% of death because of PE.39 Patients with 
fractures  of  the  pelvis  or  femur  are  also  at  high  risk.  The  increased  risk  after  cast 
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immobilization of tibial fractures is particularly well documented, with an overall VTE 
rate of 45%, but only one third of those being symptomatic.40
Malignancy and VTE
An association between malignancy and VTE was first recognized in 1864 by Armand 
Trousseau in patients with occult carcinoma and this increased risk of thrombosis due to a 
combination  of  factors.41 From a  pathogenic  view,  patients  with  cancer  often  have  a 
hypercoagulable  state  due to  the production of substances  with procoagulant  activity, 
particularly tissue factor and cancer procoagulant and tumors can compress veins causing 
stasis,  and cancer  patients  are  exposed to hospitalization,  surgery,  and chemotherapy, 
which all increase their risk. Clinical thromboembolism was estimated to occur in up to 
10%  of  cancer  patients,  and  is  the  second  leading  cause  of  death.42,43 Conversely, 
approximately 20% of patients with symptomatic DVT suffer from previously established 
malignancy44. However, thromboembolism can precede the diagnosis of malignancy by 
months or even years45. Advanced cancers are associated with a high incidence of VTE, 
especially cancers of the breast, lung, brain, pelvis, rectum, pancreas, and gastrointestinal 
tract. Administration of chemotherapy increases risk, like those documented in patients 
with myeloma on treatment with Thalidomide.46,47 In addition, women with breast cancer 
who undergo chemotherapy in association with surgery have 3 times the risk of VTE 
compared  with  women  who  undergo  surgery  alone48.  In  another  study  cancer  was 
reported in 39% patients with ultrasound confirmed DVT49.  Of these, 62% had active 
cancer, and 38% had a past history of cancer. Of those with active cancer, 54.6% were 
receiving  chemotherapy  and  17.3%  were  receiving  radiation  therapy  at  the  time  of 
diagnosis of acute DVT. Active cancer patients were younger, likely to be male, and had 
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a lower average body mass  index (BMI).  Among the patients with active cancer and 
documented cancer type, lung, colorectal, breast, lymphoma, brain, and prostate cancer 
were the most common. Common DVT risk factors among patients with active cancer 
included surgery within the prior three months, previous cigarette smoking, immobility,  
hospitalization  within  30  days,  and  prior  VTE.  However  in  multivariable  regression 
analysis, only presence of an indwelling central venous catheter and lack of prophylaxis 
remained independent risk factors for developing DVT in active cancer patients. 
Central venous catheter induced thrombosis
Central venous catheters (CVCs) in the form of surgically tunneled catheters, or totally 
implanted venous access devices, are increasingly being used for long duration infusion 
chemotherapy.50,51 Although these devices have revolutionized the clinical management 
of cancer patients, they are associated with several complications,  including infection, 
catheter thrombosis and pulmonary embolism (PE). Catheter-related venous thrombosis 
can lead to considerable morbidity, occasional mortality, and the loss of catheters. The 
diagnosis  of  upper  extremity  deep  venous  thrombosis  (UEDVT)  is  increasing  and 
constitutes about 18% of all DVTs. About 7–9 % of patients with UEDVT have been 
reported to develop acute PE.52 The reported incidence of catheter-related thrombosis 
varies considerably ranging from 12–60% in various studies.53 The wide variability in 
incidence of catheter-related thrombosis is due in part to the differences in catheter type, 
position,  and  duration  of  insertion,  type  of  malignancy  and  use  of  different 
chemotherapeutic agents. Catheter-related thrombosis is frequently under-diagnosed, as 
most patients are asymptomatic or have non-specific symptoms.  
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Recurrent venous thromboembolism
Venous thrombosis is often a chronic condition, with recurrence rates estimated at 5% to 
7% annually  after  a  first  episode.54,55 The  risk  is  highest  among  those  whose  initial 
episode was associated with cancer, and lowest among those whose initial episode was 
associated with a temporary risk factor such as surgery.55 In one study, older age and 
obesity  were  associated  with  higher  recurrence  risks.55 Recent  reports  suggest  an 
approximate  60% higher  recurrence risk among men compared to women.56 The risk 
appears  to  be  highest  in  the  6  to  12  months  following  cessation  of  anticoagulation, 
regardless of the initial  duration of anticoagulation.57 In a case–control study, patients 
with a history of VTE were approximately 8 times more likely to develop a new episode 
during a subsequent high-risk period compared with patients without a history of DVT or 
PE.58 Other  risk factors  for  recurrent  thrombosis  include  residual  vein  thrombosis  on 
ultrasound, PE as the first thrombosis event, and proximal versus distal limb deep vein 
thrombosis.
Congestive Heart or Respiratory Failure
Patients  with  congestive  heart  or  respiratory  failure  are  also  at  risk  of  venous 
thromboembolic complications. In the Prophylaxis in Medical Patients with Enoxaparin 
(MEDENOX) trial, 15% of patients with class III or IV heart failure treated with placebo 
had a confirmed episode of VTE.59 Similarly, 16% of patients with class III or IV heart 
failure treated with low-dose subcutaneous heparin in the Thromboembolism Prevention 
in Cardiopulmonary Disease with Enoxaparin (PRINCE) study developed VTE.60
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Oral Contraceptives
As oral estrogen compounds became widely available  in the late  1960s,  early reports 
suggested an alarming incidence of VTE in young and otherwise healthy women taking 
oral estrogen to prevent conception.61 Overall risk for thrombosis in oral contraceptive 
users is about threefold higher than for non-users and is highest during the first year of 
use.62,63 Lowering  the  oestrogen  dose  reduces  risk  for  thrombosis.61 Preparations 
containing  third-generation  progestogens  are  associated  with  an  increased  risk  for 
thrombosis compared with levonorgestrel. 61 Oral contraceptives enhance thrombosis risk 
in  families  with  a  natural  inhibitor  deficiency.64 A  20–30-fold  increased  risk  for 
thrombosis in heterozygous women with factor V Leiden65 and a 16-fold enhanced risk in 
women with the prothrombin mutation66 have been reported during oral contraceptive 
intake. However these numbers have to be set into perspective with the very low absolute 
risk for deep vein thrombosis in young women.67 
Hormone replacement therapy
In women receiving hormone-replacement therapy (HRT), the estrogen dose is generally 
20% to 25% of that contained in modern oral contraceptives. Despite the much lower 
biological potency, women taking HRT have a 2- to 4-fold increased risk of idiopathic 
venous thrombosis compared with women not taking HRT.68,69,70 Women with a history of 
VTE who are using HRT are at greater risk of recurrence than those with a similar history 
but  not  on  hormonal  therapy.71 Progestagen  is  added  to  estrogen  therapy  among 
postmenopausal women with an intact uterus to prevent the elevated risk of estrogen-
induced endometrial hyperplasia and adenocarcinoma. Concomitant progestagen use was 
associated with an increased VTE risk compared with the use of estrogen alone.  The 
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mechanisms  underlying  the  increased  VTE  risk  among  users  of  oral  estrogen  or 
transdermal  estrogen combined  with  norpregnane derivatives  include  a  prothrombotic 
state, a decreased blood flow, and/or an alteration in the vessel wall.72
Acquired Lupus Anticoagulants and the Antiphospholipid Syndrome 
Antiphospholipid thrombosis syndromes, which include not only the lupus anticoagulant 
(LA)  and  anticardiolipin  antibodies  (ACLAs)  but  also  more  recently  recognized 
‘‘subgroups’’  of  antiphospholipid  antibodies  (antibodies  against  beta-2-glycoprotein-I 
[B-2-GP-I])  and  antibodies  to  phosphatidylserine,  phosphatidylethanolamine, 
phosphatidylglycerol, phosphatidylinositol, phosphatidylcholine, and anti-annexin-V, all 
comprise the antiphospholipid thrombosis syndromes. Antiphospholipid syndrome is the 
most  common acquired  blood protein  defect  associated  with either  venous or arterial 
thrombosis or both. The thrombotic and thrombo-occlusive events associated with these 
antiphospholipid antibodies include thrombosis of the venous system, the arterial system, 
coronary  artery  thrombosis,  cerebrovascular  thrombosis,  transient  cerebral  ischemic 
attacks (TIAs), retinal vascular thrombosis, and placental vascular thrombosis (leading to 
recurrent-miscarriage syndrome). 
The antiphospholipid thrombosis syndrome consists of closely related but clearly distinct 
clinical  syndromes that often are discordant  with respect  to types  of antiphospholipid 
antibodies found; these syndromes are 
(1) The LA-thrombosis syndrome, 
(2) The ACLA-thrombosis syndrome, and 
(3) Thrombosis associated with subgroups of antiphospholipid antibodies. 
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The ACLA-thrombosis antiphospholipid syndrome is much more common than the LA-
thrombosis antiphospholipid syndrome, the ratio being approximately 5:1.
The anticardiolipin syndrome is associated more commonly with both arterial and venous 
thrombosis, including typical deep vein thrombosis and pulmonary embolus, premature 
coronary artery disease, premature cerebrovascular disease and retinal arterial and venous 
occlusive  disease.  Patients  with  anticardiolipin  thrombosis  syndrome  develop  more 
predictable types of thrombosis than those with the LA-thrombosis syndrome. 
The  LA,  although  sometimes  associated  with  arterial  disease,  more  commonly  is 
associated with venous thrombosis with or without pulmonary embolus. 
Patients with thrombosis harboring antibodies to B-2-GP-I or antibodies to other protein 
epitopes  mentioned  above  tend  to  more  closely  resemble  patients  with  ACLAs  than 
patients  with  isolated  LA.  Anti-annexin-V  antibodies  are  the  newest  ‘‘subgroup 
Antiphospholipid  antibody’’  to  be noted  in  association  with both arterial  and venous 
thrombosis.
Annexin  V,  actually  a  protein  bound  to  phospholipids,  is  an  important  vascular 
component, and antibodies directed against this moiety seem to disrupt endothelium and 
endothelial function and lead to associated thrombotic tendencies.72 
Although all of these antiphospholipid antibody–thrombosis syndromes may be seen in 
association with systemic lupus erythematosus, other connective tissue and autoimmune 
disorders, and other selected medical conditions such as lymphomas, most individuals 
(approximately 90%) developing any of the antiphospholipid thrombosis syndromes are 
otherwise healthy individuals and harbor no other underlying medical condition. These 
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patients  are  classified  as  having  primary,  rather  than  secondary,  antiphospholipid 
thrombosis syndrome.73 
Lupus anticoagulants and thrombosis
In 1952, Conley and Hartmann described a coagulation disorder in  two patients  with 
systemic lupus erythematosus; the patients exhibited anticoagulant  activity by in vitro 
testing, which was manifested by a prolonged whole blood clotting time and prothrombin 
time.74 Most commonly, the LA develops in otherwise healthy individuals (primary LA-
thrombosis  syndrome).  There  is  also  an  association  with  drug  ingestion;  commonly 
associated drugs include chlorpromazine, procainamide, quinidine, hydralazine, Dilantin, 
interferon, Fansidar, and cocaine.75 
Patients with the LA are at increased risk for thromboembolic disease, most commonly 
deep  vein  thrombosis,  pulmonary  emboli,  and  thrombosis  of  other  large  vessels.76 
Thromboembolism  occurs  in  approximately  10%  of  patients  with  systemic  lupus; 
however, in patients with systemic lupus and the LA, thromboembolism occurs in up to 
50% of patients. In patients harboring a primary LA, the LA is estimated to account for 
approximately 6% to 8% of thrombosis in otherwise healthy individuals. 
Although  patients  also  may  have  arterial  events,  this  is  uncommon  in  primary  LA-
thrombosis  syndrome,  as  opposed  to  primary  ACLA-thrombosis  syndrome,  in  which 
arterial events are almost as common as venous events. This observation is in distinction 
to patients with secondary LA-thrombosis syndrome, wherein patients more commonly 
experience arterial events than do those with primary LA-thrombosis syndrome. Even in 
secondary LA-thrombosis  syndrome,  however,  venous events  are  more  common than 
arterial events. Although the LA is associated with thrombosis, the mechanisms whereby 
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thrombosis occurs remain unclear. It has been proposed that there might be an interaction 
with the vasculature, thereby altering prostaglandin release. There may be activation of 
platelets and changes in prostaglandin metabolism, or the antibodies may block protein C 
or the activated protein C pathway,  or they may alter  phospholipids interactions with 
activated factor V.  77 It also has been proposed that there may be hyperactivity of the 
fibrinolytic  system and increased  levels  of  plasminogen activation  inhibitor.   Despite 
many  proposed  mechanisms,  to  date  there  remains  no  consensus  on  the  precise 
mechanisms of action of LAC’s.78 
Hemolytic anemia’s
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disorder of bone 
marrow  stem cells.  Patients  generally  manifest  chronic  intravascular  hemolysis,  with 
episodes  of  gross  hemoglobinuria  accompanied  by leukopenia  and thrombocytopenia. 
Despite the presence of thrombocytopenia, thrombosis is more commonly encountered 
than bleeding.  Indeed, thrombosis can be a presenting feature of PNH, as well  as an 
important cause of morbidity and mortality in this disorder. 
A  unique  feature  of  PNH  is  the  predilection  for  thrombosis  to  occur  in  the  intra-
abdominal  venous network  (mesenteric,  hepatic,  portal,  splenic,  and renal  veins)  and 
cerebral vessels, as opposed to deep vein thrombosis or pulmonary embolism.79 
Thrombosis  also  is  a  serious  complication  in  patients  with  other  types  of  hemolytic 
anemias, including sickle cell disease and thalassemia. In sickle cell disease, increased 
blood viscosity due to sickled erythrocytes contributes to microvascular occlusion. There 
is evidence for endothelial activation and increased numbers of circulating microvascular 
endothelial cells (CD36+) over expressing intercellular adhesion molecule-1 (ICAM-1), 
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vascular cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin, and tissue factor in 
patients  with sickle  cell  disease.80 As standards  of  care  for  thalassemic  patients  have 
improved in recent years, resulting in an almost doubling of life expectancy, previously 
un-described  complications  of  the  disease  are  being  recognized,  particularly 
thromboembolic  complications.81 These  include  cerebral  thrombosis,  deep  vein 
thrombosis, pulmonary embolism, and recurrent arterial occlusions. Venous thrombosis 
develops following splenectomy in some patients. In a Turkish study82 a total 30 patients 
(15 female, 15 male) with thalassemia major (n: 16), thalassemia intermedia (n: 11) and 
S-ß thalassemia (n: 3) were included in the study and the effects of thrombocytosis and 
natural inhibitors on thrombosis after  splenectomy were investigated.  Thrombosis was 
detected in the portal vein system in 7/30 (23.3%) of splenectomized patients. There was 
no statistical increase of platelet count in patients with or without thrombosis. Natural 
inhibitor levels in all patients were lower than controls (p< 0.001), but there was not any 
statistical difference between the patients with and without thrombosis.
Myeloproliferative disorder and hyperviscosity 
Thrombosis  can  be  a  manifestation  of  diseases  associated  with  hyperviscosity. 
Hyperviscosity  of  the  blood may  be  due  to  increased  plasma viscosity,  an  increased 
number of red or white blood cells, or decreased deformability of cells.
Hyperviscosity plays an important role in the pathogenesis of thrombosis in polycythemia 
vera, which is a major complication of this disorder. Patients with elevated hematocrits 
have increased whole blood viscosity, and this abnormality has been inversely correlated 
with cerebral  blood flow.  Common thrombotic  complications  in this  disorder  include 
cerebrovascular accidents, myocardial infarction, peripheral arterial occlusion, deep vein 
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thrombosis, pulmonary embolism, and portal and hepatic vein thrombosis (Budd-Chiari 
syndrome).
In the  myeloid  and monocytic  leukemias,  the  presence  of  very elevated  white  blood 
counts  (generally  greater  than  100,000/mL3)  can  increase  the  viscosity  in  the 
microcirculation, which can play a role in the pathogenesis of thrombosis. Small vessels 
in the lungs, brain, and, less commonly, other organs may be obstructed by high levels of 
immature leukocytes.
Inherited thrombophilia
The first  case  of  inherited  thrombophilia  was  described in  1965 by Egeberg73,83 in  a 
publication  on  a  Norwegian  family  with  a  remarkable  tendency  to  develop  venous 
thrombosis, which was shown to be due to a deficiency of the physiologic anticoagulant 
antithrombin.  In  the  1980s,  protein  C84 and  protein  S85 deficiencies  were recognized. 
Activated protein C (APC) resistance was identified by Dahlback et al in 199386as a risk 
factor for venous thrombosis in 1993. In 1994, Bertina et  al  found that factor V was 
involved in APC resistance. Subsequently, the factor V Leiden mutation was found by 
searching the factor V gene of APC resistant patients for mutations in APC binding- and 
cleavage  sites.  The  second  common  genetic  factor,  prothrombin  20210  G/A,  was 
identified  in  1996  through  screening  the  prothrombin  gene  for  abnormalities  among 
patients with a personal and family history of venous thrombosis  by Poort et  al.87 At 
present, the three plasma protein deficiencies and the two mutations are the main genetic 
risk  factors  for  venous  thrombosis.  However,  they  still  explain  only  part  of  venous 
thrombotic events.88
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Thus  now  in  >50%  of  patients  with  juvenile  or  idiopathic  thrombosis,  an  inherited 
thrombophilic  condition  can  now  be  identified.  The  predisposing  defects  do  not 
necessarily cause continuous clinical impairment but they need only weaken the ability to 
cope  with  fluctuations  induced  by  interactions  with  the  environment.  Patients  with 
thrombophilia can present fulminantly who, without therapy thrombose continuously, but 
in  most  patients  thrombosis  is  episodic,  separated  by  often  prolonged  asymptomatic 
periods. The discontinuity suggests that there is some trigger for each event, perhaps a 
direct stimulus or a temporary deterioration of intrinsic resistance, or some combination 
of these factors, which further enhance the risk. Undoubtedly the concept of inherited 
thrombophilia is an operational one, the definition of which has undergone continuous 
refinement.  It  was  originally  based  upon  early  presentation  of  thrombosis,  usually 
coupled  with  inherited  phenotypic  abnormality  of  one  of  the  inhibitory  proteins, 
antithrombin, PC or PS. Progress in the molecular basis of thrombosis has enabled a more 
genetically based definition to be formulated.  Inherited thrombophilia  is  a genetically 
determined  tendency  to  venous  thromboembolism  Dominant  abnormalities  or 
combinations of less severe defects may be clinically apparent from early age of onset, 
frequent recurrences or family history. Instead milder traits maybe discovered only by lab 
investigations. It is important to emphasize that thrombophilia is even now diagnosed on 
clinical grounds.73 Major criteria are listed in Table 2.73 
Table-2     Most Common Features of Thrombophilia      
Recurrent venous thromboembolism
Thrombosis in an unusual site (cerebral sinuses, mesenteric, 
portal)
Venous thromboembolism at a young age
Family history of venous thromboembolism
Recurrent fetal loss
Pre-eclampsia, HELLP syndrome
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Inherited  thrombophilic  disorders  (Table-3)  can  be  divided  into  loss-of-coagulation 
function  disorders  and  gain-of-coagulation  function  disorders.89 Loss-of-function 
disorders include deficiencies of the endogenous anticoagulants antithrombin, protein C, 
and protein S. They are less common than gain-of-function disorders but may be more 
potent risk factors for thrombosis. Gain-of-function disorders include factor V Leiden, 
the prothrombin G20210A variant, and possibly elevation of procoagulant factors such as 
factor VIII, von Willebrand factor, and factors V, VII, IX, and XI. These may be weaker 
risk factors for venous thromboembolism in general. 
Table 3- Inherited thrombophilia
Natural inhibitor deficiency
• Protein C
• Protein S
• Anti-thrombin 
Hyperhomocysteinaemia /MTHFR mutations
Prothrombin G20210A
APC resistance (Factor V Leiden)
High factor VIII or factor IX
Dysfibrinogenaemia or hyperfibrinogenaemia
Antiphospholipid antibody syndrome
Fibrinolytic pathway defect
Others
Blood coagulation system
The  current  concept  of  blood  coagulation  is  that  it  is  initiated  by  small  amounts  of 
encrypted  TF  which  circulate  in  blood  bound  to  microparticles  comprising  small 
phospholipids vesicles with bound proteins. On local enrichment of these particles, the 
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concentration  of  TF  exceeds  a  certain  threshold  needed  to  trigger  coagulation.  This 
combines with small amounts of activated factor VII (VIIa) in the circulation to form 
TF:VIIa complexes. The FVIIa-TF complex directly activates Factor X and generates Xa, 
which  along  with  FVa  activates  prothrombin  and  converts  it  to  small  amounts  of 
thrombin. This small amount of thrombin generated at sites of vascular injury expresses 
several  procoagulant  properties.  In  a  positive  feedback  reaction,  it  converts  the 
procofactors FV and FVIII into their biologically active forms FVa and FVIIIa.90 More 
recently, it has become apparent that thrombin also plays a positive feedback role through 
the activation of FXI.91 Small amounts of FXIa catalyze the formation of FIXa, which in 
turn activates  FX, thus enforcing  thrombin  formation.  In addition,  thrombin  activates 
platelets and ultimately converts fibrinogen into fibrin.92 Further functions of thrombin, 
aimed  at  the  generation  of  a  stable  fibrin  plug,  comprise  the  activation  of  the 
transglutaminase  FXIII  into  its  activated  form  and  the  activation  of  the  thrombin-
activatable fibrinolysis inhibitor (TAFI). These processes stabilize the fibrin clot, FXIIIa, 
by cross-linkage of fibrin monomers and TAFI through the inhibition of fibrinolysis.93
Protein C system
The highly efficient  reactions  of  the coagulation  system have considerable  biological 
potential, and strict regulation is therefore required. To this end, several plasma proteins 
and  multiple  cell-cell  and  cell-matrix  interactions  are  involved  in  the  continuous 
monitoring of the circulation. At each level of the coagulation pathway, membrane-bound 
molecules expressed on the surface of intact endothelial cells, circulating inhibitors, or 
negative feedback mechanisms provide efficient control.94,95 Similar processes of limited 
proteolyses that govern the formation of procoagulant enzymes are also involved in the 
24
down-regulation of the activities of activated clotting factors. Most strikingly, thrombin 
itself  is  the key factor  to  the initiation  of a  natural  anticoagulant  pathway called  the 
protein C anticoagulant system.
A key event at the initiation of the protein C pathway is when thrombin alters its substrate 
specificity and changes from a procoagulant to an anticoagulant protein. This change is 
dependent on the presence of thrombomodulin (TM), a transmembrane thrombin receptor 
present  on  intact  endothelium.  Thrombin  bound  to  TM  has  lost  its  procoagulant 
properties but rapidly activates protein C in a process that is enhanced by the endothelial 
cell protein C receptor (EPCR).96 Protein C is a vitamin K-dependent protein circulating 
in plasma at a concentration of 50 to 80 nM.97 During activation of protein C by the 
thrombin-TM-EPCR complex,  a 12-amino acid activation peptide is released,  and the 
activated protein C exhibits a highly specific proteolytic activity, cleaving only a limited 
number of peptide bonds in FV/FVa and FVIIIa.98
Protein C deficiency
Deficiencies of protein C may be either congenital or acquired.99 Congenital deficiency is 
autosomal  dominant  and  characterized  by  recurrent  venous  thrombosis  and 
thromboembolism  beginning  in  adolescence.92 Most  homozygous  patients  die  of 
thromboembolic  disease  in  infancy.92 Both  absence  and  dysfunctional  forms  of  the 
disorder are observed. Type I disease is characterized by reduction in both antigenic and 
functional levels to less than 50% and type II, in which functional levels are decreased 
much more than antigenic levels. 92 Studies of the genetic defects in patients with protein 
C  deficiency  have  led  to  the  identification  of  more  than  160  different  mutations.100 
Heterozygous protein C deficiency is inherited in an autosomal dominant fashion. The 
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phenotype of patients with heterozygous protein C deficiency is similar to that of persons 
with hereditary antithrombin III deficiency. In severely affected families, approximately 
75% of  protein  C-deficient  persons  experienced  one or  more  thrombotic  events.  The 
initial  episode  occurs  apparently  spontaneously  in  approximately  70%  of  those 
experiencing  such events.  The  remaining  30% have the  usual  associated  risk  factors 
(pregnancy,  parturition,  contraceptive  pill  use,  surgery,  or  trauma)  at  the  time  they 
develop acute thrombotic events. 
The most common sites of disease are the deep veins of the legs, the iliofemoral veins, 
and  the  mesenteric  veins.  Approximately  63% of  affected  patients  develop  recurrent 
venous  thrombosis,  and  approximately  40% exhibit  signs  of  pulmonary  embolism.101 
Superficial thrombophlebitis of the leg veins as well as cerebral venous thrombosis can 
occur in protein C-deficient patients.102,103 
The prevalence of protein C deficiency in outpatients presenting with an initial episode of 
venous thromboembolism ranges  from 0.5% to 4%.104,105,106 In earlier  reports  of  more 
selected patient populations, protein C deficiency was more frequently identified, ranging 
from 2% to 9%.107,108 In the general population, the prevalence of protein C deficiency is 
between 1:200 and 1:500, as documented by mass screening of blood donors.109,110
Protein S system
Protein S, an important cofactor to APC, is also a vitamin K-dependent plasma protein, 
circulating in plasma. In human plasma, approximately 40% of protein S is free, and the 
remaining  60% is  bound to  the  complement  regulatory  C4b-binding  protein  (C4BP). 
Only the free form functions as APC cofactor. 
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The  mechanism by which  free  protein  S  acts  as  a  cofactor  to  APC is  not  yet  fully 
understood. It has been suggested that protein S exerts its APC cofactor activity through 
enhancement of the binding of APC to phospholipid surfaces. In the absence of protein S, 
inactivation of membrane bound FVa proceeds primarily through the cleavage of two 
peptide bonds at Arg 506 and Arg 306. Cleavage at Arg 506 is kinetically preferred over 
that  at  Arg  306,  showing  an  approximate  20-fold  difference  in  overall  reaction  rate. 
However FXa has been shown to protect the Arg506 site. Moreover, cleavage at Arg506 
does  not  fully  abrogate  FVa  activity,  and  complete  loss  of  FVa  activity  requires  a 
subsequent (slower) cleavage at Arg306. Protein S specifically promotes the cleavage at 
Arg306. Thus, in the presence of both FXa and protein S, though the preferred cleavage 
at Arg506 is blocked, FVa is readily inactivated through the cleavage at Arg306.111
Protein S deficiency
In 1984, members from several kindreds who exhibited reduced levels of protein S were 
described  who  had  a  striking  history  of  recurrent  venous  thrombotic  disease.112 
Subsequently, many additional families with this disorder have been reported. 
Heterozygous protein S deficiency is inherited in an autosomal dominant fashion, with a 
reported  frequency of  approximately  10% in families  with inherited  thrombophilia.113 
However, the prevalence is less (between 1% and 7%) among consecutive outpatients 
with deep vein thrombosis.97,98   Protein S deficiency generally is considered to confer a 
risk of thrombosis similar to that in protein C deficiency.114,115
The clinical presentation of patients with heterozygous protein S deficiency is similar to 
that outlined for deficiencies of antithrombin III and protein C. Of 71 protein S-deficient 
members  from  12  Dutch  pedigrees,116 74%,  72%,  and  38%  sustained  deep  vein 
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thrombosis, superficial thrombophlebitis, and pulmonary emboli, respectively. The mean 
age at the first thrombotic event was 28 years,  with a range of 15 to 68; 56% of the 
episodes  apparently  were  spontaneous,  and  the  remainder  were  precipitated  by  an 
identifiable factor.  Thrombosis also has been reported in the axillary,  mesenteric,  and 
cerebral veins.
Three types of protein S deficiency states can be identified on the basis of measurements 
of total  and free antigen as well as functional activity (Table-4). Type I deficiency is 
associated  with approximately 50% of the normal  total  protein S antigen level117 and 
decrements  in  free  protein  S  antigen  and  protein  S  functional  activity  to  less  than 
approximately 40% of normal.118 Another type of hereditary deficiency (type II) has been 
described in which the functional activity of protein S is decreased, but with normal total 
and free antigen levels. A type III deficiency state is characterized phenotypically by a 
decreased concentration of free and functional plasma protein S but a normal level of 
total protein S antigen. 
         Table 4 Assay Measurements in Heterozygous Protein S Deficiency 
Type Protein S Total Antigen Free Protein S Activity
I ("classic") Low Low Low
II Normal Normal Low
III Normal Low Low
Type I deficiency most often is secondary to missense mutations, base pair insertions or 
deletions, premature stop codons, or mutations affecting a splice site. There have been a 
few cases  of  large  deletions  of  the  gene.  Of  the  more  than  130  different  mutations 
documented  in  patients  with  various  types  of  protein  S  deficiency,  only  7  different 
nucleotide substitutions have been identified with a type II deficiency. 119 Several of these 
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mutations are located in the N-terminal end of the protein S molecule, which includes the 
domains that interact with activated protein C.120 The biologic basis of type III protein S 
deficiency state is uncertain.
Antithrombin
The  concept  of  antithrombin  stems  from  P.  Morawitz  in  1905  who  considered  it 
responsible  for  the  gradual  loss  of  thrombin  activity  after  blood  had  clotted.121 
Antithrombin  is  a  glycoprotein  inhibitor  that  functions  by  neutralizing  coagulation 
proteases (fig-3), by forming a 1:1 complex between the enzyme and antithrombin (AT). 
This reaction probably accounts for the major mechanism of inhibition of thrombin and 
factors Xa and XIa, but the reaction is slow in the absence of heparin. Heparin accelerates 
inhibition of the coagulation proteases about 1000-fold. As a result, antithrombin must be 
present for heparin to function as an effective anticoagulant. With thrombin, optimal rates 
of  inactivation  require  the  simultaneous  interaction  of  heparin  with  antithrombin  and 
thrombin.122 Heparin  acts  as  a  bridge  between  thrombin  and  antithrombin,  thereby 
concentrating the reactants and accelerating the reaction. In addition, the interaction of 
heparin  with  antithrombin  alters  the  conformation  of  the  inhibitor,  which  makes  the 
protease  "trap"  more  accessible  to  thrombin  and the  other  coagulation  factors.115  The 
vascular  endothelium  and  the  microvascular  endothelium  in  particular,  are  rich  in 
anticoagulantly active heparin-like proteoglycans, which are endothelial cell-associated 
proteins with heparin side chains bearing the critical carbohydrate sequences required for 
antithrombin recognition. Both thrombin and antithrombin bind to sulfated carbohydrates 
and  are  brought  into  close  proximity  to  each  other.  Antithrombin  undergoes  a 
conformational  change required for  rapid  inactivation  of  thrombin.  Heparin  functions 
29
catalytically,  facilitating  the  rapid  dissociation  of  the  thrombin/antithrombin  complex 
from the proteoglycan. This critical step is responsible for re-exposure of the heparin sites 
for binding with other thrombin and antithrombin molecules.
                              
Antithrombin III Deficiency
Antithrombin  III  deficiency  is  inherited  in  an  autosomal  dominant  fashion  and  thus 
affects both genders equally.  Two major types of inherited antithrombin III deficiency 
have  been delineated.  The type  I  deficiency state  is  a  result  of  reduced  synthesis  of 
biologically  normal  protease  inhibitor  molecules.123 In  these  cases,  the  antigenic  and 
functional activity of antithrombin III in the blood is reduced in parallel. The molecular 
basis of this disorder is either a deletion of a major segment of the antithrombin III gene 
or,  more  commonly,  the  occurrence  of  small  deletions/insertions,  or  single  base 
substitutions. These mutations will introduce a frameshift, a direct termination codon, a 
change in messenger  RNA (mRNA) processing,  or unstable  translation  products.  The 
antithrombin III mutation database includes 80 distinct mutations in patients with a type I 
deficiency.124 The second type of antithrombin III deficiency is produced by a discrete 
molecular  defect  within  the  protease  inhibitor  (type  II).  The  plasma  levels  of 
Figure-3
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antithrombin  III  are  greatly  reduced  as  judged  by  functional  activity,  whereas 
antithrombin  III  immunologic  activity  is  essentially  normal.  The  prevalence  of 
antithrombin III deficiency in the adult population is approximately 1/2000.125 Studies of 
healthy blood donors employing functional assays that measure heparin cofactor activity 
have found that the prevalence of antithrombin III deficiency in the general population is 
1/250 to 1/500. 
The  initial  clinical  manifestations  occur  apparently  spontaneously  in  about  42%  of 
persons but are related to pregnancy, parturition, use of oral contraceptives, surgery, or 
trauma in the remaining 58% of patients.126 The most common sites of disease are the 
deep veins of the leg and the mesenteric veins. Recurrent thrombotic episodes occur in 
approximately 60% of affected persons, and clinical signs of pulmonary embolism are 
evident in 40%.119   Thrombotic episodes are rare in affected children before puberty. At 
this  time,  thrombotic  events  start  to  occur  with  some  frequency,  and  the  risk  of 
thrombosis  increases  substantially  with  advancing  age.119 First-degree  relatives  of 
symptomatic persons with antithrombin III deficiency have an 8- to 10-fold increased risk 
of thrombosis  over that  in noncarriers.106 In the Leiden Thrombophilia  Study,  a case-
control  study  of  474  consecutive  patients  following  an  initial  episode  of  deep  vein 
thrombosis,127 the prevalence of antithrombin III deficiency was only 1.1%, and the odds 
ratio for thrombosis was only 5.0.98
Factor V – Physiology 
FV is a large single chain glycoprotein of approximately 330 kDa. Even though several 
cellular  types  have been reported to  synthesize  FV, the principal  site  of  biosynthesis 
remains the liver. Human FV is synthesized as a single-chain molecule that undergoes 
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extensive posttranslational modifications before it is secreted into the blood. FV has a 
mosaic-like structure, with a domain organization A1-A2-B-A3-C1-C2 (Fig. 4) that is 
similar to that of FVIII.128 
Circulating single-chain FV is an inactive procofactor with the potential to express either 
procoagulant or anticoagulant activities after proteolytic modification by procoagulant or 
anticoagulant enzymes (Fig. 4). Cleavage of FV by either FXa or thrombin results in the 
conversion of FV to the procoagulant cofactor FVa, whereas APC-mediated cleavage of 
intact FV converts the molecule to an anticoagulant species with the capacity to support 
APC in the degradation of FVIIIa. (Fig-5) The APC-cofactor activity of FV and that of 
protein S are synergistic, and only in the presence of both proteins is the FVIIIa in the  
tenase complex efficiently inhibited by APC.129,130  
Figure-4 Domain structure of factors V. The large B domain 
separates the A2 and A3 domains. The three A domains are 
arranged in a triangular fashion, with the B domain extending 
from the A2 and A3 domains (b). Thrombin-mediated cleavages 
at Arg709, Arg1018, and Arg1545 (A, upper black arrows) result 
in B-domain liberation and activation of FV. Active FVa 
comprises the A1-A2 heavy chain noncovalently bound to the 
A3-C1-C2 light chain, and the C2 domain localizes the protein to 
negatively charged phospholipid membranes (c). Proteolytic 
inactivation of FV(a) catalyzed by APC proceeds through 
peptide bond cleavages at Arg306, Arg506, Arg679, and Lys994, 
as indicated by the lower arrows (a).130
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Figure-5130
The dual functions of FV suggest that it can act as a local sensor of procoagulant and 
anticoagulant  forces.  In  the  event  the  procoagulant  enzymes  FXa  and  thrombin  are 
generated,  FV  is  converted  to  a  procoagulant  FXa  cofactor.  In  contrast,  if  APC 
predominates, FV is converted to an anticoagulant molecule functioning as APC cofactor. 
Circulating  single-chain FV expresses less than 1% of the procoagulant  FXa-cofactor 
activity  it  can maximally obtain.  Activation  of  FV by procoagulant  enzymes  such as 
thrombin and FXa comprises the limited proteolysis of three peptide bonds at Arg709 
(between A2 and B), Arg1018 and Arg1545 (between B and A3), resulting in an increase 
of  the  FXa-cofactor  activity.131 These  cleavages  result  in  dissociation  of  the  large 
connecting  B domain  (Fig.  4)  from FVa.  APC cleaves  FVa at  Arg306,  Arg506,  and 
Arg679. As a consequence of these cleavages,  the peptides  generated dissociate  from 
each other, thereby inducing a loss of cofactor activity. In the degradation of FVIIIa, the 
activity of APC is enhanced several-fold by the presence of the protein cofactors protein 
S and intact FV.132 It has been observed that full activation of FV—that is, after cleavage 
at  Arg709 and Arg1545, resulting in  the release of the B domain,  leads  to  a  loss  of 
anticoagulant activity of FV.122  
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FV Leiden-induced APC resistance
In  1993,  Dahlbäck133 identified  a  novel  mechanism  for  familial  thrombophilia;  the 
plasmas  of  persons  with  unexplained  personal  and  familial  histories  of  venous 
thromboembolism exhibited a poor response to activated protein C (APC) in a PTT assay. 
The observations of Dahlbäck facilitated the development of a PTT-based assay to screen 
for APC resistance. In a U.S. referral population of patients younger than 50 years of age 
with unexplained venous thromboembolic  disease,  approximately  50% were found to 
have APC resistance.134 Investigators in Italy and Austria confirmed that APC resistance 
was a frequent laboratory abnormality in patients with unexplained venous thrombosis.135
In 1987, Dutch investigators from Leiden initiated the Leiden Thrombophilia Study, a 
large case-control study to investigate risk factors for first episodes of venous thrombosis 
in the general population of The Netherlands.136 It was shown that a defect in factor V 
involving the mutation -Arg506Gln, or factor V Leiden is most often the cause of APC 
resistance.137 This is the site at which APC cleaves factor Va, and this sequence alteration 
makes  the  mutant  factor  Va  molecule  biochemically  resistant  to  inactivation  by  the 
enzyme.130,138 The Arg506Gln substitution was found to be the cause of APC resistance in 
about 90% of Dutch patients with APC resistance on the PTT assay, and the mutation 
was found in 2% to 4% of healthy Dutch controls. Most patients with APC resistance are 
heterozygous for the factor V Leiden mutation, but a number of homozygous patients 
with heightened APC resistance on PTT assays have been identified.130 Homozygotes are 
at higher thrombotic risk than that noted for heterozygotes.139
34
FVLeiden and thrombosis
The estimated risk for thrombosis from the presence of the FVLeiden mutation is similar 
to that of other genetic defects affecting the protein C anticoagulant pathway. The relative 
risk in heterozygous carriers of the FVLeiden mutation is increased 5- to 7-fold, whereas 
it  is  increased  up  to  80-fold  for  homozygous  persons.  Thromboembolic  episodes 
associated  with  FVLeiden are  almost  exclusively  venous  in  nature.  The severity  and 
localization of thrombosis in carriers of FVLeiden is diverse. Common are thromboses in 
the deep veins of the leg,140 whereas portal vein thrombosis, superficial vein thrombosis, 
and  cerebral  vein  thrombosis  are  less  prevalent.  However,  primary  pulmonary 
embolism141 does not seem to be associated with the FVLeiden mutation. Combinations 
of other thrombotic risk factors, either genetic or acquired, and FVLeiden appear to have 
a synergistic effect. Factor V Leiden and as well as other hereditary thrombophilia the 
prothrombin gene mutation are associated with an approximate tripling of the risk of late 
fetal  loss.142,143 An  increased  incidence  of  factor  V  Leiden,  as  well  as  other 
thrombophilias,  also  was  reported  in  women  in  association  with  other  obstetric 
complications.144
The prevalence of heterozygosity for the factor V Leiden mutation in whites, including 
European, Jewish, Israeli Arab, and Indian populations, ranges between 1% and 8.5%.145 
APC resistance in the absence of the FV Leiden mutation
Already in the earliest reports on APC resistance, it was noted that there was no 100% 
association between the presence of the FV Leiden mutation and APC resistance.130 In 
approximately 5% of all patients with phenotypic APC resistance, the Arg506Gln was 
absent. Two mutations at the Arg306 residue in factor V, the second APC cleavage site in 
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the  activated  cofactor,  have  been described  in  patients  with  a  history  of  thrombosis. 
These mutations are replacement of Arg306 with threonine (factor V Cambridge)146 and 
with glycine (in Hong Kong Chinese).147 For both FV forms, the observed APC resistance 
phenotype was intermediate between normal FV and FV Leiden. 
Prothrombin G20210A mutation 
The prothrombin G20210A mutation in the 3’ UTR was first described by Poort et al in 
199678 and results in elevated plasma prothrombin levels and an increased risk of venous 
thrombosis.148 This mutation is located at the last position of the 3'-untranslated region at 
the cleavage site for polyadenylation of prothrombin mRNA changes the position of the 
3'-cleavage/polyadenylation reaction in prothrombin mRNA, thereby leading to increased 
prothrombin  biosynthesis  by  the  liver.149 The  gene  mutation  now  is  known  to  be 
associated  with  both  arterial  and  venous  thrombosis.  Subsequently,  Brown  et  al150 
reported  a  study  of  504  patients  with  venous  thromboembolism,  and  2.6%  of  this 
population was positive for the prothrombin G20210A gene mutation. Prothrombin gene 
mutation,  similar  to the factor V Leiden mutation,  seems to be rare in individuals  of 
African  and  Asian  decent.  In  the  Leiden  Thrombophilia  Study,  6.2%  of  venous 
thrombosis  patients  and 2.3% of  healthy matched controls  had the  prothrombin  gene 
mutation.139 
Hyperhomocysteinemia and thrombosis
Homocysteine metabolism151 - Remethylation and transsulfuration
Homocysteine is  an intermediary in the methionine cycle  (Fig.6).  Methionine derived 
from dietary sources is first converted into S-adenosylmethionine (SAM). This important 
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intermediate serves as the key methyl donor for a large number of biochemical reactions. 
After  donating a methyl  group, SAM is converted to S-adenosylhomocysteine,  which 
undergoes hydrolysis to form adenosine and homocysteine. 
Figure-6153
Homocysteine is remethylated to form methionine by one of two pathways. The major 
pathway is remethylation by methionine synthase (MS) in a reaction that requires vitamin 
B12 as a cofactor and converts N5-methyltetrahydrofolate (MTHF) to tetrahydrofolate 
(THF). THF is recycled into MTHF in a two-step process; the first step converts THF to 
N  [5],N10-  methylenetetrahydrofolate,  and  the  second  converts  N  [5],N10-
methylenetetrahydrofolate  back  to  5-methylTHF.  This  second  step  is  catalyzed  by 
methyltetrahydrofolate reductase, an enzyme under much study because of a common 
mutation  that  produces  mild  hyperhomocysteinemia.  The  minor  homocysteine 
remethylation pathway that uses betaine as a methyl donor becomes important clinically 
in the treatment of patients with homocystinuria. The methionine cycle and the linked 5-
methylTHF regeneration cycle form the primary pathway of homocysteine metabolism 
known as the remethylation pathway. 
Alternatively,  homocysteine  can  be  metabolized  by  the  transsulfuration  pathway. 
Homocysteine  can  condense  with  serine  to  form  cystathionine  by  the  action  of 
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cystathionine b-synthase (CBS). A congenital deficiency of this enzyme causes most of 
the homocystinuria cases associated with early-onset atherosclerosis. 
MTHFR mutations: Cys677Thr
Mutations that severely reduce MTHFR activity are rare. In 1988, Kang et al152 reported a 
thermolabile  mutation  of  MTHFR associated  with  less  specific  enzyme  activity  and 
hyperhomocysteinemia. In 1994 the MTHFR gene was cloned, and, shortly thereafter, 
Frosst et al153 identified the common polymorphism of MTHFR (Cys677Thr) that showed 
thermolability  and  produced  hyperhomocysteinemia.  This  point  mutation  replaces  an 
alanine with a valine residue in the enzyme.
It is now known that the Cys677Thr mutant allele occurs at high frequency in Europe (up 
to  50%)154 and  variable  frequency  in  Asia  (approximately  45% in  Koreans,  30% in 
Chinese).155,156 Given the high T-allele frequency in many populations, heterozygosity and 
homozygosity are common. It has been consistently shown that heterozygotes have no 
significant levels of hyperhomocysteinemia, and homozygotes (TT genotype) have raised 
tHcy values by an average of 25%. 157,158
Homocysteine is able to promote vascular smooth muscle cell proliferation and inhibit 
endothelial  cell  growth.159 Moderate  hyperhomocysteinemia  induced  by  dietary 
manipulation leads to vascular dysfunction with impaired vasomotor responses, as well as 
decreased  thrombomodulin  activity  in  the  aorta.  The  thrombogenic  effects  of 
hyperhomocysteinemia that have been demonstrated in vitro include induction of tissue 
factor expression,160 inhibition of heparan sulfate expression, inhibition of nitric oxide 
and prostacyclin  release,  inhibition  of  tissue-type  plasminogen  activator  binding,  and 
inhibition of thrombomodulin-dependent protein C activation.161
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A  relationship  between  hyperhomocysteinemia  and  venous  thrombosis  is  now 
appreciated. Studies of patients who have an initial episode of venous thrombosis before 
age 45 demonstrate that 13% to 18% have moderate hyperhomocysteinemia.162 A Dutch 
study showed that 25% of patients with recurrent venous thrombosis had homocysteine 
levels above the 90th precentile of those in healthy controls, and the presence of this 
abnormality  conferred  a  two-fold  increased  risk  of  recurrence.163 In  the  Leiden 
Thrombophilia Study, an elevated homocysteine level exceeding the 95th percentile of 
the control group was found in 10% of patients and conferred a twofold increased risk of 
thrombosis.  The risk of  thrombosis  was increased  20-fold in  patients  with  idiopathic 
thrombosis who were both hyperhomocysteinemic and had the Factor V Leiden mutation.
Other plasma coagulation Factors
Factor VIII
Activated factor VIII (FVIII) is the cofactor for activated factor IX (FIX) in the activation 
of factor X (FX). In 1995, Koster et al studied the influence of ABO blood group, levels 
of VWF and levels of FVIII on the risk of a first venous thrombosis in the first 301 
patients and 301 controls of the LETS.164 In individuals with FVIII levels over 150 IU/dL 
the risk of thrombosis increased nearly fivefold compared to individuals with levels lower 
than 100 IU/dL. The results from the LETS have been confirmed in a number of other 
independent studies.165,166 Besides increasing the risk of a first venous thrombosis, high 
levels  of  FVIII  also may increase  the risk of  recurrences.167 The mechanism through 
which high FVIII levels could influence thrombosis risk has not been fully clarified. It 
has been reported that high levels of FVIII associate with decreased APC sensitivity. 168 
High levels of FVIII can drastically increase thrombin generation.169 
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Factor IX
In 2000, Van Hylckama Vlieg et al reported that individuals with FIX levels over the 
90th percentile (>129 U/dL) have a nearly threefold increase in thrombosis risk when 
compared to  individuals  with levels  below this  cutoff value in the LETS.170 The risk 
remained after adjustment for possible confounders. The risk of thrombosis appeared to 
increase linearly with FIX levels. The authors reported that the risk was slightly higher in 
women than in men and that the risk was highest in premenopausal women not using oral 
contraceptives.  Similar  findings  were found in a  study consisting  of  66 women with 
venous  thromboembolism  (VTE)  and  163  controls  between  the  ages  of  45  and  64 
years.171 After adjustment for hormone replacement therapy, women with high FIX levels 
(>150 U/dL) had a 2.3-fold increase in the risk of VTE. In an Austrian study, it was  
found  that  high  levels  of  FIX  also  increase  the  risk  of  recurrence  after  a  previous 
thrombosis.172 High levels of FIX increased the risk of recurrence caused by high levels 
of FVIII from 2.7 to 6.6. 
Hyperfibrinogenemia/ Dysfibrinogenemia
In 1994, Koster et al173 first described the association between high levels of fibrinogen 
and the risk of a first venous thrombosis. In 199 patients and 199 healthy control subjects 
from the Leiden Thrombophilia Study (LETS), individuals with fibrinogen levels over 5 
g/L had a nearly fourfold increase in risk of venous thrombosis. Furthermore, there was a 
dose-response relationship between levels of fibrinogen and the risk of thrombosis. A 
2003 reanalysis of the LETS included 474 patients and 474 healthy controls.174 Again, an 
increase in the risk of thrombosis was observed for high levels of fibrinogen. 
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Qualitative abnormalities of fibrinogen, inherited in an autosomal dominant manner, are a 
heterogeneous group of disorders that may be asymptomatic or manifest with a bleeding 
diathesis or recurrent venous or arterial thromboembolism. A small  number of variant 
fibrinogens  have  been  reported  to  be  associated  with  thrombotic  complications.  The 
functional and biochemical defects of a number of abnormal fibrinogens associated with 
thromboembolic  disease  have  been  characterized.175 The  conversion  of  fibrinogen  to 
fibrin by thrombin results in the proteolytic cleavage of fibrinopeptides A and B from the 
molecule.  Defects  in  the  release  of  these  two  peptides  or  abnormalities  in  fibrin 
polymerization have been reported. In one of the affected kindreds, three homozygous 
siblings with a Bβ chain substitution of Ala by Thr at position 68 had a severely affected 
clinical phenotype and sustained both arterial and venous thrombosis at a young age.176 
Decreased binding of thrombin by this mutant fibrinogen has been suggested to lead to 
the presence of excessive thrombin in the circulation and the occurrence of thrombosis. 
Other  fibrinogen mutants  have  been  shown to  cause  abnormal  fibrin  polymerization. 
Some  of  the  abnormal  fibrinogens  have  been  evaluated  for  their  ability  to  resist  or 
promote fibrinolysis on incorporation into a fibrin clot.
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DESIGN AND OBJECTIVES
Objectives of the study
• To  study  the  clinical  and  laboratory  profile  of  patients  with  documented 
thrombosis, which includes- Deep vein thrombosis, pulmonary embolism, cortical 
sinus  thrombosis  and  Budd  Chiari  syndrome  due  to  thrombosis  of  hepatic  or 
Inferior  vena  caval  venous  system,  who  presented  to  the  Christian  Medical 
College and Hospital from January 2005 till June 2007.
• To study the incidence of inherited thrombophilias in patients with documented 
thrombosis.
Design of the study
This study is a retrospective analysis of patients with venous thromboembolism. The case 
records and the laboratory data of patients with documented venous thromboembolism 
were analyzed. The diagnosis of thrombosis was based on radiological evaluation- by 
Colour doppler ultrasonography in cases of deep vein thrombosis and CT angiogram, 
Magnetic resonance imaging and angiogram , where indicated.
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PATIENTS AND METHODS
Patients who were referred for evaluation of risk factors for venous thromboembolism 
from January 01, 2005 to June 30, 2007 were initially taken. From this group, the patients 
who had documented thrombosis in our institution were included for this study. Clinical 
details,  including  date  of  diagnosis  of  thrombosis,  site  of  thrombosis,  family  history, 
recurrence and details of anticoagulation were obtained from the patients’ records. The 
thrombophilia risk workup comprises the following tests:
Complete blood counts
Plasma coagulation tests
• Prothrombin time
• Activated partial thromboplastin time
• Thrombin time
Factor VIII assay
Fibrinogen assay
Natural inhibitors of coagulation
• Protein C assay
• Protein S assay
• Antithrombin assay
Activated protein C resistance
PNH workup
• Ham’s and sucrose lysis test
Sickle preparation 
Antiphospholipid antibody syndrome
• Dilute Russell’s viper venom test (DRVVT)
DNA  mutations  predisposing  for  thrombosis,  comprising  of  Factor  V  Leiden 
(Arg506Gln), Prothrombin (G20210A) and MTHFR (Cys677Thr) mutations were done 
in the Hematology department, whenever requested for.
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RESULTS
Between the year January 2005 and June 2007, a total of 266 patients with documented 
thrombosis were evaluated for risk factors of thrombosis in our institution. The median 
age  of  presentation  was  38  years  (range:  4-74).  4  (1.5%)  were  4-15  years  old,  183 
(68.8%) were between 16-45 years and 79 (29.7%) were between 46-74 years (Table 1). 
There were 140 (52.6%) males and 126 (47.4%) females in our group. This study group 
contained 38 (14.3%) patients with history of recurrent thrombotic events and only 10 
(3.8%) with a positive family history of thrombosis (Table 2). None of the 4 patients in 
the less than 15 years group had either family history or history of recurrent episodes. 
21/183 (11.5%) and 17/79 (21.5%) patients had history of recurrence and 7/183 (3.8%) 
and 3/79 (3.8%) patients had a positive family history in the 16-45 and 46-74 years age 
groups respectively. 
Table 1: Age distribution
Age (yrs) Number %
4-15 4 1.5
16-45 183 68.8
46-74 79 29.7
Total 266 100
Table 2: History of recurrence and family history
Recurrence history Family history
Number % Number %
Presen
t
38 14.3 10 3.8
Absent 228 85.7 256 96.2
Total 266 100 266 100
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Thrombosis in the deep veins of the limbs were the most common site of thrombosis in 
this group, seen in 123 (46.2%) of patients, followed by cortical sinus thrombosis in 92 
(34.6%) of patients. Pulmonary embolism as the presenting complains was seen in 26 
(9.8%)  patients  and  Budd  Chiari  syndrome  with  thrombosis  of  the  hepatic  veins  or 
inferior vena cava in 20 (7.5%) patients (Table 3). 
Table 3: Site of thrombosis at presentation
Site Number of patients %
Deep vein thrombosis (DVT) 123 46.2
Cortical sinus thrombosis (CST) 92 34.6
Pulmonary embolism (PE) 26 9.8
Budd Chiari syndrome (BCS) 20 7.5
CVT + DVT 4 1.5
DVT + PE 1 0.4
Total 266 100
Among patients with deep vein thrombosis, proximal lower limb veins were affected in 
82 (64.1%), followed by abdominal veins in 32 (25%) patients. Distal veins of the lower 
limb, upper limb veins, veins of the neck or chest or extensive thrombosis,  involving 
more than 2 sites were seen in 4 (3.2%), 5 (3.8%), 4 (3.2%) and 1 (0.7%) respectively. 
Patients with Budd Chiari syndrome had thrombosis of the hepatic vein in 15 (75%), 
Inferior vena cava in 2 (10%) and both in 3 (15%) patients.  
In our group 121 (45.5%) patients were on anticoagulant therapy. Of these 79 (65.3%) 
patients were on oral anticoagulation and 42 (34.7%) were on parenteral (Low molecular 
weight or un-fractionated heparin) Table 4.
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Table 4: Patients on anticoagulation
Anticoagulation Number %
Oral 79 65.3
Parenteral LMWH 42 24 34.7 19.8
UFH 18 14.9
Total 121 100
Acquired etiological factors of thrombosis.
Etiological factors contributing for development of thrombosis were present in 55/266 
(20.7%) patients.  The breakdown of the etiological  factors between the three groups- 
Venous  thromboembolism  (VTE),  cortical  sinus  thrombosis  (CST)  and  Budd  Chiari 
syndrome (BCS) is given in Table 5. 
30/154 (19.5%) patients  with  venous  thromboembolism,  19/92  (20.6%) patients  with 
cortical  sinus  thrombosis  and  6/20  (30%)  patients  with  Budd  chiari  syndrome  had 
documented etiological factors as detailed below. 
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Table 5: Acquired etiological factors 
Etiological factors Whole group 
(n-266)
VTE
(n-154)
CST
(n-92)
BCS
(n-20)
Lupus anticoagulant 21/266 (7.9%) 17/154 (11.0%) 3/92 (3.2%) 1/20 (5%)
Malignancies
Acute lymphoid leukemia 2/266 (0.7%) - 2/92 (2.2%) -
Acute promyelocytic leukemia 1/266 (0.4%) 1/154 (0.6%) - -
Myelofibrosis 1/266 (0.7%) - 1/92 (1.1%) -
Polycythemia 5/266 (1.9%) 4/154 (2.4%) 1/92 (1.1%) -
Lymphoma 1/266 (0.4%) 1/154 (0.6%) - -
Others
Post surgery 4/266 (1.4%) 2/154 (1.2%) - 2/20 (10%)
Post partum 12/266 (4.4%) 1/154 (0.6%) 11(11.9%) -
Oral contraceptives 2/266 (0.7%) - - 2/20 (10%)
Tb Meningitis 1/266 (0.4%) - 1/92 (1.1%) -
Rheumatoid arthritis 1/266 (0.4%) 1/154 (0.6%) - -
Chronic liver disease 2/266 (0.7%) 1/154 (0.6%) - 1/20 (5%)
Pancreatitis 2/266 (0.7%) 2/154 (1.2%) - -
Total 55/266 (20.7%) 30/154(19.5%) 19/92(20.6%) 6/20(30%)
Blood counts
The median hemoglobin of our whole group was 12 gm% (5.2 – 19.5), total white cell 
count was 8200/cmm (1300-57800), and platelet count 274000/cmm (10,000-12, 74,000). 
Plasma coagulation tests
The median prothrombin time of patients in this study group was 12.6 (8.9-104.3) sec, 
activated partial thromboplastin time was 30.4 (20.1-166.5) sec and thrombin time was 
13.9 (10.7-32) sec. Activated partial thromboplastin time was shortened below the normal 
range in 13 (4.9%) of patients. 
Plasma coagulation factors
Plasma  coagulation  factors  evaluated  in  this  group  of  patients  were  factor  VIII  and 
fibrinogen.   The mean factor  VIII  level  in  this  study group was 305% (74-725) and 
fibrinogen level was 318 mg% (156-649). Hyperfibrinogenemia with levels of fibrinogen 
more than 450 mg% was seen in 28 (10.5%) patients. Fibrinogen levels were elevated in 
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1/4 (25%) patient, 20/183 (10.9%) patients and 7/79 (8.9%) patients in the age groups 4-
15 years, 16-45 years and 46-74 years respectively. Since two studies in the past have 
demonstrated significant risk of thrombosis and recurrence of thrombosis if factor VIII 
levels are more than 250 Iu/dL177 or 294 Iu/dL178, the cut off for significant elevation of 
factor  VIII  levels  was  taken  as  >  250 Iu/dL.  Thus  159/266 (59.7%) of  patients  had 
elevated factor VIII levels. 48/266 (18%) patients had levels more than 450%, 41/266 
(15.4%) had levels ranging between 351-450%, 70 (26.3%) patients had levels between 
251-350%. (Table 6)
Table 6: Elevated factor VIII levels
Factor VIII No %
251-350 70/266 26.3
351-450 41/266 15.4
>450 48/266 18.0
Total 159/266 59.7
Natural inhibitors of coagulation
Protein C and S system
The median protein C level in this group was 96 IU/ml (10-287) and that of protein S was 
79 IU/ml (12-778). Protein C and S levels were decreased below 50 IU/ml in 27 (10.2%) 
and 48 (18%) of patients. Both protein C and S levels were decreased in 14 (5.3%) of 
patients. 20 (74.1%) patients with protein C deficiency were on oral anticoagulation and 
only 7 (25.9%) were not on any anticoagulation. Similarly 35 (72.9%) of patients with 
protein S deficiency were on anticoagulation and only 13 (27.1%) of patients were not on 
anticoagulation  and  all  14  patients  with  decreased  protein  C  and  S  levels  were  on 
anticoagulation. In effect only 7/266 (2.6%) or 13/266 (4.8%) patients had a decreased 
protein C or S level not attributed to anticoagulation.
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Antithrombin
The median antithrombin level in this group was 109 % (12-778). Levels less than 80 %, 
considered as decreased were seen in 23 (8.6%) of patients. Three of these patients were 
on parenteral anticoagulation (UFH-2 and LMWH-1) at the time of evaluation. Thus in 
20/266 (7.5%) patients, low AT levels could be considered a true risk factor.
Activated protein C ratio
The median APC ratio was 2.78 (1.06-5.48) and activated protein C resistance, revealed 
by a reduced APC ratio (< 2) was seen in 15 (6%) of patients (Table 7).  
Table 7: APCR and factor V Leiden mutation
Normal APCR Shortened APCR Total
No % No % No %
Negative 174 93.0 13 7.0 187 92.1
Heterozygous 14 93.3 1 6.7 15 7.4
Homozygous - - 1 100.0 1 0.5
Total 188 92.6 15 7.4 203 100
Factor  V Leiden  mutation  was  the  cause  of  this  resistance  in  only  2/15  (13.4%)  of 
patients. Similarly of the 16 patients positive for factor V Leiden mutation only 2 (12.5 
%) had activated protein C resistance. 
DNA mutations predisposing thrombosis
DNA markers for thrombosis was done in 203 (76.3%) of patients. The DNA markers 
evaluated were Factor V Leiden mutation, Prothrombin G20210A mutation and MTHFR 
Cys677Thr  polymorphism.  It  has  been  well  documented  that  only  MTHFR  677TT 
(homozygous) genotype contributes a significant amount to hyperhomocysteinemia.161,162 
Hence the homozygous genotype alone was considered as a risk factor. There were no 
risk factors  identified  in  133 (65.5%) of  patients  and mutations  were  detected  in  25 
(12.3%) of  patients.  The incidence  of  Factor  V Leiden  mutation  was 16/203 (7.9%), 
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prothrombin mutation was 2/203 (1.0%) and MTHFR mutation was 7/203 (3.4%). One 
patient  was  homozygous  for  factor  V  Leiden  mutation  and  7  patients  for  MTHFR 
homozygous 677TT mutation (Table 8).
Table 8: DNA mutations predisposing thrombosis
DNA marker Status Number 
(n-203)
%
V Leiden Heterozygous 15 7.4
Homozygous 1 0.5
Prothrombin Heterozygous 2 1.0
MTHFR Homozygous 7 3.4
Total      25/ 203 12.3  
Sickle cell disease and PNH 
There were no patients with PNH and only 2 (0.8%) patients with sickle cell disease and 
thrombosis in this group.
Table 9: Lupus anticoagulant (Dilute Russell’s viper venom time-DRVVT)
DRVVT Number % Cumulative %
Moderate positive 14 5.3
7.9Marked Positive 7 2.6
Mild positive * 68 25.6 25.6*
Negative 177 66.5 66.5 
Total 266 100.0 100.0
       * 25.6% patients with mild positive DRVVT were excluded because the test was to be repeated.
Acquired and inherited risk factors
DVT rarely occurs in the absence of risk factors and these risk factors are cumulative in 
their effect. The risk factors evaluated in our study were 
Acquired risk factors 7. Factor VIII > 250 Iu/dL
History of recurrence 8. Hyperfibrinogenemia
Positive family history 9. Factor V Leiden mutation
Protein C deficiency 10. Prothrombin G20210A mutation
Protein S deficiency 11. Homozygous MTHFR mutation
Antithrombin deficiency 12. Activated protein C resistance
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Table 10: Multiple risk factors
Number of risk 
factors
Frequency % Cumulative Cumulative %
Risks No
6 1 0.4 > 5 1 0.4
5 3 1.1 > 4 4 1.5
4 7 2.6 > 3 11 4.1
3 31 11.6 > 2 42 15.8
2 62 23.3 > 1 104 39.1
1 59 22.3
Subtotal of patients 
with risk factors 
163 61.3
0- No risk factors 103 38.7
Total 266 100.0
In our study 163/266 (61.3%) of patients had at least one risk factor. 59/266 (22.3%) had 
only one risk factor, while 104/266 (39.1%) had more than 1 risk factors. 62/266 
(23.3%) had 2 risk factors, 31/266 (11.6%) had 3 risk factors, 7/266 (2.6%) had 4 
risk factors, 3/266 (1.1%) had 5 risk factors and 1/266 (0.4%) had 6 risk factors 
(Table 10).
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Subgroup analysis of patients with venous thromboembolism
Between  the  year  January  2005  and  June  2007,  a  total  of  154  patients  had  venous 
thromboembolism (Deep vein thrombosis + pulmonary embolism). These patients were 
evaluated separately for risk factors of thrombosis. The median age of presentation was 
42 years (range: 8-74). There were 96 (62.3%) males and 58 (37.7%) females in this 
subgroup (Table 12). This study group contained 27 (17.5%) patients  with history of 
recurrent thrombosis and 7 (4.5%) patients with family history of thrombosis (Table 11). 
Table 11: History of recurrence and family history
Recurrence history Family history
Number % Number %
Present 27 17.5 7 4.5
Absent 127 82.5 147 95.5
Total 154 100 154 100
In our group 70 (45.5%) patients were on anticoagulant therapy. Of these 48 (68.6%) 
patients were on oral and 22 (31.4%) were on parenteral anticoagulation (Table 12).
Table 12: Patients on anticoagulation
Anticoagulation Number %
Oral 48 68.6
Parenteral LMWH 22 13 31.4 18.6
UFH 9 12.9
Total 70 100
Blood counts
The median hemoglobin of our whole group was 12 gm% (5.2 – 19.5), total white cell 
count was 7900/cmm (1300-57800), and platelet count 267000/cmm (12,000-12, 74,000). 
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Plasma coagulation tests
The median prothrombin time of patients in this study group was 12.6 (9.1-104.3) sec, 
activated partial thromboplastin time was 30.3 (22.8-166.5) sec and thrombin time was 
14 (10.7-18) sec. Activated partial thromboplastin time was shortened below the normal 
range in 5 (3.2%) of patients. 
Plasma coagulation factors
Plasma  coagulation  factors  evaluated  in  this  group  of  patients  were  factor  VIII  and 
fibrinogen.   The mean factor  VIII  level  in  this  study group was 275% (74-725) and 
fibrinogen level was 304 mg% (156-649). Hyperfibrinogenemia with levels of fibrinogen 
more than 450 mg% was seen in 20 (13%) patients. 90/154 (58.4%) of patients had factor 
VIII levels more than 250 Iu/dL. 27/154 (17.5%) patients had levels more than 450%, 
24/154  (15.6%) had  levels  ranging  between  351-450%,  27/154  (17.5%) patients  had 
levels between 251-350%. 
Natural inhibitors of coagulation
Protein C and S system
The median protein C level in this group was 98 IU/ml (10-171) and that of protein S was 
78 Iu/ml (12-157). Protein C and S levels were decreased below 50 IU/ml in 12 (7.8%) 
and 28 (18.2%) of patients. Both protein C and S levels were decreased in 6 (3.9%) of 
patients. 9 patients with protein C deficiency were on oral anticoagulation and only 3 
were not on any anticoagulation. Similarly 17 of patients with protein S deficiency were 
on anticoagulation and 11 patients were not on anticoagulation and all 6 patients with 
decreased protein C and S levels were on anticoagulation. In effect only 3/154 (1.9%) or 
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11/154  (7.1%)  patients  had  a  decreased  protein  C  or  S  level  not  attributed  to 
anticoagulation.
Antithrombin
The median antithrombin level in this group was 108% (40-149). Levels less than 80%, 
considered as decreased were seen in 16 (10.4%) patients. Three of these patients were on 
parenteral  anticoagulation  (UFH-2 and LMWH-1)  at  the  time  of  evaluation.  Thus  in 
13/154 (8.4%) patients, low AT levels could be considered a true risk factor.
Activated protein C ratio
The median APC ratio was 2.79 (1.48-5.48) and activated protein C resistance, revealed 
by a reduced APC ratio (< 2) was seen in 6 (3.9%) of patients.  
DNA mutations predisposing thrombosis
DNA markers for thrombosis was done in 111 (72.1%) of patients. There were no risk 
factors identified in 96 (86.5%) of patients and mutations were detected in 15 (13.5%) of 
patients. The incidence of Factor V Leiden mutation was 10/111 (9.0%), prothrombin 
G20210A mutation  was 1/111 (0.9%) and homozygous  MTHFR mutation  was 4/111 
(3.6%). (Table 13)
Table 13: DNA mutations predisposing thrombosis
DNA marker Status Number
(n-111)
%
V Leiden Heterozygous 10 9.0
Prothrombin Heterozygous 1 0.9
MTHFR Homozygous 4 3.6
Total 15/ 111 13.5  
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Sickle cell disease and PNH 
There were no patients with PNH and only 1 (0.6%) patient with sickle cell disease and 
thrombosis in this group.
Lupus anticoagulant (Dilute Russell’s viper venom time-DRVVT)
Table 14: Lupus anticoagulant
DRVVT Number % Cumulative %
Moderate positive 11 7.1
11.0Marked Positive 6 3.9
Mild positive* 39 25.4 25.4*
Negative 98 63.6 63.6
Total 154 100.0 100.0
* 25.4% patients with mild positive DRVVT were excluded because the test was to be repeated.
Acquired and inherited risk factors in patients with VTE
In 154 patients with venous thromboembolism, 97 (63%) had at least one risk factor. 
34/154 (22.2%) had only one risk factor, while 63/154 (40.9%) had more than 1 
risk factor. 39/154 (25.3%) had 2 risk factors, 21/154 (13.6%) had 3 risk factors, 
2/154 (1.3%) had 4 risk factors and 1/154 (0.6%) had 5 risk factors. More than 2, 3 
and 4 risk factors were seen in 15.6%, 1.9% and 0.6% of patients  respectively 
(Table 15).
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Table 15: Multiple risk factors
No of risk factors Frequency % Cumulative Cumulative 
%Risks No
6 0 0 > 5 0 0
5 1 0.6 > 4 1 0.6
4 2 1.3 > 3 3 1.9
3 21 13.6 > 2 24 15.6
2 39 25.3 > 1 63 40.9
1 34 22.2
0 57 37.0
Total 154 100.0
Subgroup analysis of patients with cortical sinus thrombosis
Between the year January 2005 and June 2007, a total of 92/266 (34.6%) patients had 
thrombosis  involving  the  cortical  sinus  system,  documented  with  medical  resonance 
imaging with or without angiogram, and were analyzed separately.  The median age of 
presentation  was  33  years  (range:  4-65).  There  were  34  (37%) males  and 58 (63%) 
females in this subgroup. A positive family history of thrombosis was there in 2 (2.2%) 
patients in this subgroup and history of recurrence was present in 9 (9.8%) of patients.
Counts and plasma coagulation tests
The median hemoglobin in this subgroup was 12 gm% (5.5 – 18.0), total white cell count 
was 8300/cmm (1600-23300), and platelet count 287000/cmm (10,000-777000).
The median prothrombin time of patients in this study group was 12.3 (8.9-83.8) sec, 
activated partial thromboplastin time was 30.1 (20.1-138.6) sec and thrombin time was 
13.8 (11.0-24.2) sec. 
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Anticoagulation
In this subgroup 46 (50%) of patients were on some kind of anticoagulation. 29 (63%) 
patients were on oral anticoagulation and 17 (37%) were on parenteral (Low molecular 
weight-8 and un-fractionated heparin-7).
Plasma coagulation factors
The mean factor VIII level in this subgroup was 273 Iu/dL (83-719) and fibrinogen level 
was 307 Iu/dL (158-590). Hyperfibrinogenemia with levels of fibrinogen more than 450 
mg% was seen in 8 (8.7%) patients. Elevated factor VIII levels (>250 Iu/dL) was seen in 
56 (60.8%) of patients.  Of patients with elevated factor VIII levels 17 (21%) patients had 
levels more than 450 Iu/dL, 13 (16%) had levels ranging between 351-450 Iu/dL and 26 
(32.1%) patients had levels between 251-350 Iu/dL.
Natural anticoagulants
Protein C and S system
The median protein C level in this subgroup was 105 IU/ml (16-287) and that of protein S 
was 80 IU/ml (14-778). Protein C and S were decreased below 50 Iu/ml in 12 (13%) and 
19 (20.7%) of patients. Both protein C and S were decreased in 8 (8.7%) of patients. 
10/12  (83.3%)  of  patients  with  protein  C  deficiency  were  on  oral  anticoagulation. 
Similarly 17/18 (94.4%) of patients with protein S deficiency were on anticoagulation. 
All patients with decreased protein C and S levels were on anticoagulation. In effect only 
2/92 (2.2%) patients  with  protein  C deficiency and 1/92 (1.1)  patient  with  protein  S 
deficiency could not attributed to anticoagulation. 
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Antithrombin
The median antithrombin level in this group was 119% (40-188). Levels less than 80%, 
considered as decreased were seen in only 1 (1.1%) of patients. This patient was not on 
LMWH or UFH and this deficiency could not be attributed to this.
Activated protein C ratio
The median APC ratio was 2.26 (1.06-3.48) and activated protein C resistance, revealed 
by a  reduced APC ratio  (< 2)  was seen  in  4 (10.5%) of  patients.   Factor  V Leiden 
mutation was the cause of this resistance in only 1/4 (25%) of patients. 
DNA mutations predisposing thrombosis
DNA markers for thrombosis was done in 77 (83.7%) of patients. There were no risk 
factors identified in 69 (89.6%) of patients and mutations were detected in 8 (10.4%) of 
patients.  All  positive  patients  had  only  single  mutations.  The  incidence  of  Factor  V 
Leiden mutation was 4/77 (5.2%), prothrombin G20210A mutation was 1/77 (1.3%) and 
homozygous MTHFR Cys677Thr mutation was 3/77 (3.9%). 
Lupus anticoagulant
Antiphospholipid antibody syndrome,  due to lupus anticoagulant  was positive in 3/92 
(3.3%) of patients. 
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Acquired and inherited risk factors in patients with CST
In 92 patients with cortical  sinus thrombosis,  53 (57.6%) had at least one risk factor.  
20/92 (21.7%) had only one risk factor, while 33/92 (35.9%) had more than 1 risk 
factor. 28/92 (30.4%) had 2 risk factors, 3/92 (3.3%) had 3 risk factors and 2/92 
(2.2%) had 4 risk factors. More than 2 and 3 risk factors were seen in 5.4% and 
2.2% patients respectively (Table 16).
Table 16: Multiple risk factors
No of risk factors Frequency % Cumulative Cumulative %
Risks No
6 0 0 > 5 0 0
5 0 0 > 4 0 0
4 2 2.2 > 3 2 2.2
3 3 3.3 > 2 5 5.4
2 28 30.4 > 1 33 35.9
1 20 21.7
0 39 42.4
Total 92 100.0
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Subgroup analysis of patients with Budd Chiari syndrome
Between the year January 2005 and June 2007, a total of 20/266 (7.5%) patients had 
Budd Chiari syndrome, due to thrombosis of the hepatic veins or the inferior vena cava 
and were analyzed separately. The median age of presentation was 30 years (range: 6-
56).  Males and females  were equally represented in this  subgroup. A positive  family 
history  of  thrombosis  was  there  in  1  (5%)  patient  in  this  subgroup  and  history  of 
recurrence was present in 2 (10%) patients.
Counts and plasma coagulation tests
The median hemoglobin in this subgroup was 13 gm% (7.0 – 16.0), total white cell count 
was 7600/cmm (4000-17600), and platelet count 232000/cmm (43000-527000).
The median prothrombin time of patients in this study group was 14.5 (11.0-24.1) sec, 
activated partial  thromboplastin time was 32.3 (23.4-49.5) sec and thrombin time was 
14.4 (11.6-32.0) sec. 
Anticoagulation
In this  subgroup 5 (25%) of patients were on some kind of anticoagulation.  2 (40%) 
patients were on oral anticoagulation and 3 (60%) patients were on low molecular weight 
heparin.
Plasma coagulation factors
The mean factor VIII level in this subgroup was 299 Iu/dL (109-574) and fibrinogen level 
was  271  Iu/dL  (170-375).  Hyperfibrinogenemia  was  not  seen  in  any patients  in  this 
subgroup. Elevated factor VIII levels (>250 Iu/dL) was seen in 13 (65%) of patients.  
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Natural anticoagulants
Protein C and S system
The median protein C level in this subgroup was 61 Iu/ml (17-212) and that of protein S 
was 94 Iu/ml (47-151). Protein C and S were decreased below 50 Iu/ml in 3/20 (15%) 
and 1/20 (5%) of patients.  1/3 (33.3%) of patients  with protein C deficiency and the 
single patient with protein S deficiency were on oral anticoagulation. In effect only 2/20 
(10%) patients with protein C deficiency could not attributed to anticoagulation. 
Antithrombin
The median antithrombin level in this group was 87% (12-142). Levels less than 80%, 
considered as decreased were seen in 6 (30%) of patients. One of these 6 patients one was 
on unfractionated heparin and this deficiency could be attributed to this. 
Activated protein C ratio
The median APC ratio was 2.95 (1.36-4.15) and activated protein C resistance, revealed 
by a reduced APC ratio (< 2) was seen in 1 (5%) of patients.  Factor V Leiden mutation 
was the cause of this resistance in only 1/4 (25%) of patients. 
DNA mutations predisposing thrombosis
DNA markers  for  thrombosis  was done in  15 (75%) of  patients.  There  were no risk 
factors  identified  in  13/15  (86.7%)  of  patients  and  mutations  were  detected  in  2/15 
(13.3%) of patients, both of whom were heterozygous for factor V Leiden mutation.
Lupus anticoagulant
Antiphospholipid antibody syndrome,  due to lupus anticoagulant  was positive in 1/20 
(5%) of patients.
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Acquired and inherited risk factors in patients with CST
In 20 patients with Budd Chiari syndrome, 13/20 (65%) had at least one risk factor. 2/20 
(10%) had only one risk factor, while 11/20 (55%) had more than 1 risk factor. 
The frequency of prothrombotic risk factors, both acquired and inherited are given in 
Table 17 and the clinical characteristics of patients in Table 18.
Table 17: Frequency of hereditary prothrombotic risk factors
Whole group
(n- 266)
VTE
(n-154)
CST
(n-92)
BCS
(n-20)
Factor V Leiden 16/203*
(7.9%)
10/111*
(9.0%)
4/77*
(5.2%)
2/15* 
(13.3%)
Prothrombin G20210A 2/203
(1.0%)
1/111
(0.9%)
1/77 
(1.3%)
0
Homozygous MTHFR 7/203
(3.4%)
4/111
(3.6%)
3/77 
(3.9%)
0
Protein C (<50 Iu/ml) 7/266
(2.6%)
3/154
(1.9%)
2/92 
(2.2%)
2/20 
(10.0%)
Protein S (<50 Iu/ml) 13/266
(4.8%)
11/154
(7.1%)
1/92 
(1.1%)
0
Antithrombin III (<80 Iu/ml) 20/266
(7.5%)
13/154
(10.4%)
1/92 
(1.1%)
5/20 
(25.0%)
Elevated factor VIII (>250 
%)
159/266
(59.7%)
90/154
(58.4%)
56/92 
(60.8%
)
13/20 
(65.0%)
Elevated fibrinogen (>450mg
%)
(10.5%)
28/266
20/154 
(13.0%)
8/92 
(8.7%)
0
Sickle cell anemia 2/266
(0.7%)
2/154
(1.2%)
0 0
Thalassemia 2/266
(0.7%)
2/154
(1.2%)
0 0
* Number of patients where DNA markers were done 
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Table 18: Overview of results
Parameters Whole 
group
VTE CST BCS
Total No No. 266 154 92 20
Median age Yrs 38 42 33 30
Males % 52.6 62.3 37 50
Family history % 3.8 4.5 2.2 5.0
Recurrence % 14.3 17.5 9.8 10.0
Anticoagulation % 45.5 45.5 50 25
Oral % 29.7 31.2 31.5 10
Heparin % 15.8 14.3 18.5 15
Hb- Median 
(range: 5.2-19.5)
gm/dl 12 12 12 13
TC- Median 
(range: 1300-57800)
No 8200 7900 8300 7600
Platelets- Median 
(range: 0.1-12.7)
x 109 2.74 2.67 2.87 2.32
Coagulation tests
PT Sec 12.6 12.6 12.3 14.5
aPTT Sec 30.4 30.3 30.1 32.3
TT Sec 13.9 14.0 13.8 14.4
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Subgroup analysis of patients with recurrent thrombosis
Between the year January 2005 and June 2007, a total of 38/266 (14.3%) patients with 
documented thrombosis had history of recurrent episodes of thrombosis in the past and 
were analyzed separately. The median age of presentation was 43 years (range: 21-73). 
There were 25 (65.8%) males and 13 (34.2%) females in this subgroup. A positive family 
history of thrombosis was there in 5 (13.2%) patients in this subgroup.
Thrombosis in the deep veins of the limbs were the most common site of thrombosis in 
this subgroup also, seen in 25 (65.8%) of patients, followed by cortical sinus thrombosis 
in 9 (23.7%) of patients.  Pulmonary embolism as the presenting complains and Budd 
Chiari syndrome with thrombosis of the hepatic veins or inferior vena cava were seen in 
2 (5.3%) patients each (Table 21). 
Table 19: Site of thrombosis at presentation
Site Number of patients %
Deep vein thrombosis (DVT) 25 65.8
Cortical sinus thrombosis (CST) 9 23.7
Pulmonary embolism (PE) 2 5.3
Budd Chiari syndrome (BCS) 2 5.3
Total 38 100
Counts and plasma coagulation tests
The median hemoglobin in this subgroup was 13 gm% (5.2 – 16.0), total white cell count 
was 7500/cmm (1300-19600), and platelet count 303000/cmm (10,000-693000).
The median prothrombin time of patients in this study group was 13.3 (10.2-81.0) sec, 
activated partial  thromboplastin time was 32.2 (23.4-56.3) sec and thrombin time was 
13.6 (11.4-16.7) sec. 
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Anticoagulation
In  this  subgroup  17  (44.7%)  of  patients  were  on  anticoagulant  therapy.  14  (82.4%) 
patients were on oral anticoagulation and 3 (17.6%) were on parenteral (Low molecular 
weight or un-fractionated heparin) anticoagulation.
Plasma coagulation factors
The mean factor VIII level in this subgroup was 322 Iu/dL (133-694) and fibrinogen level 
was 307 Iu/dL (158-460). Hyperfibrinogenemia with levels of fibrinogen more than 450 
mg% was seen in only 2 (5.3%) patients. Elevated factor VIII levels (>250 Iu/dL) was 
seen in 25/38 (65.8%) of patients.  Of patients with elevated factor VIII levels 7 (18.4%) 
patients had levels more than 450 Iu/dL, 6 (15.8%) had levels ranging between 351-450 
Iu/dL and 12 (31.6%) patients had levels between 251-350 Iu/dL.
Natural anticoagulants
Protein C and S system
The median protein C level in this subgroup was 100 Iu/ml (10-159) and that of protein S 
was 77 Iu/ml (12-156). Protein C and S were decreased below 50 Iu/ml in 4 (10.5%) and 
11 (28.9%) of patients respectively.  Both protein C and S were decreased in 3 (7.8%) 
patients.  All 4 patients with protein C deficiency were on oral anticoagulation. Similarly 
6  (54.5%) of  patients  with  protein  S  deficiency were  on  anticoagulation  and only  5 
(45.5%) patients were not on anticoagulation and all patients with decreased protein C 
and  S  levels  were  on  anticoagulation.  In  effect  only  5/38  (13.1%)  patients  had  a 
decreased S level not attributed to anticoagulation. 
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Antithrombin
The median antithrombin level in this group was 107% (62-136). Levels less than 80%, 
considered as decreased were seen in only 1/38 (2.6%) patient. This patient was also on 
LMWH and this deficiency could be attributed to this.
Activated protein C ratio
The median APC ratio was 2.26 (1.06-3.48) and activated protein C resistance, revealed 
by a  reduced APC ratio  (< 2)  was seen  in  4 (10.5%) of  patients.   Factor  V Leiden 
mutation was the cause of this resistance in only 1/4 (25%) of patients. 
DNA markers for thrombosis
DNA markers  for  thrombosis  were done in  25 (65.8%) patients.  There were no risk 
factors identified in 19 (76%) patients and mutations were detected in 6 (24%) patients. 
All  positive  patients  had  only  single  mutations.  The  incidence  of  Factor  V  Leiden 
mutation was 4/25 (16%), prothrombin and homozygous MTHFR mutation were seen in 
1/25 (4.0%) patient each.
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Subgroup analysis of patients with positive family history
Between the year January 2005 and June 2007, a total of 10/266 (3.7%) patients with 
documented thrombosis had a positive family history of thrombosis and were analyzed 
separately.  The median  age of  presentation  was 42 years  (range:  16 -73).  Males  and 
females were equally represented in this subgroup. History of recurrence was present in 5 
(50%) patients in this subgroup.
Thrombosis in the deep veins of the limbs were the most common site of thrombosis in 
this subgroup also, seen in 7 (70%) of patients, followed by cortical sinus thrombosis in 2 
(20%) of patients and Budd Chiari syndrome with thrombosis of inferior vena cava in 1 
(10%) patients. 60% of patients were on anticoagulation at the time of evaluation.
Counts and plasma coagulation tests
The median hemoglobin in this subgroup was 13 gm% (7.8 – 17.0), total white cell count 
was 8400/cmm (4800-13600), and platelet count 260000/cmm (193,000-399000).
The median prothrombin time of patients in this study group was 14.0 (9.1-57.8) sec, 
activated partial thromboplastin time was 30.2 (24-56.3) sec and thrombin time was 13.8 
(11.4-15.0) sec. 
Plasma coagulation factors
The mean factor VIII level in this subgroup was 362% (209-534) and fibrinogen level 
was 325 mg% (253-465). Hyperfibrinogenemia with levels of fibrinogen more than 450 
mg% was seen in 2 (20%) patients. Elevated factor VIII levels (>250 %) was seen in 9/10 
(90%) patients.  2 (20%) patients had levels more than 450%, 3 (30%) had levels ranging 
between 351-450% and 4 (40%) patients had levels between 251-350%.
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Natural anticoagulants
Protein C and S system
The median protein C level in this subgroup was 105 Iu/ml (59-159) and that of protein S 
was 97 Iu/ml (17-153). There was no patients with protein C deficiency and Protein S 
were decreased below 50 Iu/ml in 2 (20%) of patients.   Both patients with protein S 
deficiency were on oral anticoagulation and cannot be considered as true deficiency.
Antithrombin
The median antithrombin level in this group was 109% (88-126). There were no patients 
with antithrombin deficiency.
Activated protein C ratio
The median APC ratio was 2.72 (1.95-3.40) and activated protein C resistance, revealed 
by a reduced APC ratio (< 2) was seen in only 1 (10%) of patient.   Factor V Leiden 
mutation was not done for this patient. 
DNA mutations predisposing thrombosis
DNA markers for thrombosis was done in 6 (60%) of patients. Mutations were negative 
in 4/6 (66.7%) patients and detected in 2/6 (33.3%) patients - one (16.7%) patient each 
with factor V Leiden and homozygous MTHFR Cys677Thr mutation. 
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DISCUSSION
The present study was undertaken to evaluate  the risk factors in a selected cohort of 
patients with documented thrombosis. In this study patients referred for thrombophilia 
screening, either had venous thromboembolism (Deep vein thrombosis with or without 
pulmonary embolism), cortical sinus thrombosis and Budd Chiari syndrome (thrombosis 
of hepatic veins with or without inferior vena cava).  This is to our knowledge the second 
largest study done in India and the first from south India. The first study in India was  
from western India and they had evaluated 432 patients.179 
Clinical characteristics.
Venous thromboembolism (VTE)
154 patients were documented to have deep vein thrombosis with or without pulmonary 
embolism.  The median  age  at  presentation  in  this  group was 42 (8-74)  years.  Males 
(62.3%) outnumbered females and the male: female ratio was 1.6:1. In a case control 
study from Italy also the mean age was 47.4 (18–84) years and males comprised 48% 
(40.6-55.4) of patients.180 Similarly in two other case control studies, the median age was 
41 (9-77) years and 47.4 (18-84) years. The male: Female ratios in the same two studies 
were 1:1.3 and 1:1.1.183,181 Thromboembolic  events  are  infrequent  in children  and are 
usually a secondary complication. In the present study children below 15 years of age 
were only 1.3%. The incidence of thrombosis in children range from 0.07 to 0.14 per 
10,000  children  in  general  population,  but  5.3  per  10000  hospital  admissions  in 
children.182 The peak of the thrombotic risk is evidenced in the age group younger than 1 
year  and  during  adolescence.  Similarly  in  a  retrospective,  population-based  study  in 
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Olmsted County residents, which evaluated 2218 patients, there were only 4 patients in 
the less than 15 years age group.183
In this study 4.5% of patients had family history of thrombosis and 17.5% had history of 
recurrence.  Venous  thrombosis  is  often  a  chronic  condition,  with  recurrence  rates 
estimated at 5% to 7% annually after a first episode,6 the risk is highest among those 
whose initial episode was associated with cancer, and lowest among those whose initial 
episode was associated with a temporary risk factor such as surgery. Hron et al were not 
able to demonstrate an association between a positive family history of thrombosis with 
risk of recurrent thrombosis among 829 patients without deficiencies of protein C, protein 
S, or antithrombin.184 In another case control study by Fredrick et al the prevalence of 
recurrent history of thrombosis was 19%.185 
Cortical sinus thrombosis
92  patients  were  documented  to  have  cortical  sinus  thrombosis  by  MRI/MRA.  The 
median age at presentation in this group was 33 (4-65) years.  There were 67% females in 
this  group and the  male:  female  ratio  was 1:0.6.  ISCVT, a  prospective  multinational 
observational study had evaluated 624 consecutive patients with CVT. The Median age in 
this group was 37 yrs (18-86) and females constituted 74.5% of patients.186  In another 
study - a Meta analysis in which 17 studies and 48 - 2285 patients were included, the 
median  age  ranged  from  24  -  43  years.187 In  another  prospective  study  done  in 
Netherlands and United Kingdom, which evaluated 59 patients with CVT, the median age 
was 33 yrs (18-80) and 50/59 (84.7%) were females.188 
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Budd Chiari syndrome
20 patients in this study had Budd-Chiari syndrome (BCS), characterized by occlusion of 
hepatic outflow either at the level of the hepatic veins or inferior vena cava. Cases were 
documented by colour Doppler or angiogram. The median age of patients in this group 
was 30 yrs (6-56) and male: female ratio was 1:1. In a large multicenter population-based 
case-control study, 43 patients with BCS were evaluated. The median age of this group 
was 40 yrs (19-60) and male: female ratio was 1:0.6.189 In another study, evaluating 63 
patients with BCS, the median age was 35 yrs (12-66) and males were 23.8%.190 
Thrombophilia risk factors
Acquired risk factors
Acquired risk factors for thrombophilia in our study were present in 22.2% of patients. 
22.2% of patients with VTE, 20.6% patients with CST and 30% patients with BCS had 
acquired risk factors.  Of note 11/92 (12%) patients with cortical sinus thrombosis were 
post partum. In a study from Italy,191 130 unrelated patients with CST were evaluated. 
Transient  risk  factors  like  oral  contraceptives,  hormone  replacement  therapy, 
pregnancy/puerperium, surgery; head trauma and infection were seen in almost 60% of 
patients,  compared  to  only  16.3% in  our  group.  The cause  for  this  difference  is  not 
evident,  but  could  be  due  to  inadequate  documentation  of  risk  factors. 
Pregnancy/Puerperium was a transient risk factor in 6.2% of patients, compared to 12% 
of patients in this study. In patients with BCS the common acquired risk factors were past 
abdominal surgeries and use of oral contraceptives.  In a large multi-centre case control 
study,  evaluating  patients  with  BCS,  the  common  acquired  risk  factors  were 
myeloproliferative disorder (28%), Lupus anticoagulant in 5%, cirrhosis in 14%, previous 
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abdominal surgeries in 23% and oral contraceptives in 28%. In the other study also > 
50% of patients had documented myeloproliferative disorders. In our study abdominal 
surgeries and oral contraceptive use was seen in 20% of patients and chronic liver disease 
in 10% of patients. There were no cases of myeloproliferative disorders in our series and 
is different from studies in literature. 
Lupus anticoagulant (Dilute Russell’s viper venom time-DRVVT)
Lupus anticoagulant was seen in 7.9% of our patients. Lupus  anticoagulant was present in 
8.3% of patients in the study from western India. In some studies incidence as high as 
28% have been documented.192 In the Leiden Thrombophilia Study, a population-based 
case-control study designed to determine risk factors for deep venous thrombosis (DVT). 
Lupus anticoagulant (LAC) was measured in 473 patients and 472 control subjects. Four 
control subjects (0.9%) and 14 patients (3.1%) had a positive LAC.193
Inherited risk factors
Plasma coagulation factors
An elevated factor VIII level was the most common risk factor in this study group, and 
was seen in 59.7% of our patients. In studies from the west elevated FVIII:C (> 1.5 iu/ml) 
emerged  as  the  single  commonest  abnormality  detected  in  25.4% of  a  group of  260 
patients with venous thromboembolism in one study.194 In another study, the prevalence 
of elevated plasma levels of factor VIIIc in 65 patients with a proven single episode and 
in  60  matched  patients  with  documented  recurrent  venous  thromboembolism  were 
systematically studied. To minimize the influence of the acute phase, blood was obtained 
at least 6 months after the thromboembolic event and results were adjusted for fibrinogen 
and C-reactive protein and factor VIIIc was re-determined several years after the first 
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measurement in a subset of patients to evaluate the variability over time. In the control, 
single and recurrent episode group, the prevalence of plasma levels of factor VIIIc above 
175 IU/dl (90th percentile of controls) were 10% (95% CI: 4 to 21%), 19% (95% CI: 10 
to 30%) and 33% (95% CI: 22 to 47%), respectively.  For each 10 IU/dl increment of 
factor VIIIc, the risk for a single and recurrent episode of venous thrombosis increased by 
10% (95% CI:  0.9  to  21%)  and  24% (95% CI:  11  to  38%),  respectively. 179 In  our 
subgroup analysis, the incidence of high factor VIII in patient with history of recurrence 
was 25/38 (65.8%). Known causes of FVIII elevation, such as the acute thrombotic event 
itself; inflammation; malignancy; liver, renal, or vascular disease; surgery; or pregnancy, 
could  explain  the  high  incidence  in  our  group.  Some  groups  investigated  C reactive 
protein along with factor VIII to ascertain if the elevation was reactive or not. However in 
our study this was not done. In our study fibrinogen levels were evaluated and since 
fibrinogen is also raised in the above situations, we would expect hyperfibrinogenaemia 
in our study. However the same was found in only 10.5% of patients in our group. Hence 
it is possible, that the elevated factor VIII level in our study is probably significant. The 
genetic basis for increased coagulation factor VIII levels is not well understood at this 
time and needs to be investigated. 
Natural inhibitors of anticoagulation and DNA markers of thrombosis
The incidence of Protein C, S and AT deficiency in our study group, not attributed to 
anticoagulation  was  2.6%,  4.8% and  7.5% respectively.   In  patients  with  history  of 
recurrence there were no patients with Protein C or AT deficiency, but 13.1% of patients 
had protein S deficiency. 
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Venous thromboembolism
In patients with VTE, the prevalence of protein C, S and AT deficiency was 1.9%, 7.1% 
and 10.4%. When these were compared to data from the west and from one study from 
western India, the prevalence of protein C, S and AT III deficiencies were higher in our  
study and the other study from western India.182 However DNA markers of thrombosis are 
more prevalent in the west compared to both our data and the other from India. In our 
study 2 patients with prothrombin G20210A mutation were seen and none were reported 
in the study from the other study from India. (Table 22) 
Table 22: Etiology of venous thromboembolism – Hereditary prothrombotic risk factors
Characteristics Margaglione et al183 Tripodi et al184 Ghosh et al182
Western India
Present study
South India
No. of patients 175 605 432 154
Antithrombin 0.6% 1.7% 2.6 13/154(8.4 %)
Protein C 1.2% 1.5% 9.5 3/154 (7.1 %)
Protein S 0.6% 2.1% 6.5 11/154(10.4 %)
Factor V Leiden 16.6% 14.4% 3.0 10/111* (9.0 %)
Prothrombin G20210A 14.2% 8.3% 0 1/111* (0.9 %)
Homozygous MTHFR Not available Not available 1.2 4/111* (3.6%)
Factor VIII (>250 Iu/dl) Not available Not available Not available 90/154 (58.4%)
Fibrinogen (>450mg %) Not available Not available Not available 20/154 (13.0%)
* Number of patients for whom DNA mutations were analyzed.
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Table 23: Etiology of cortical sinus thrombosis – Hereditary prothrombotic risk factors
Characteristics Martinelli et al195 Present study
No. of patients 63 92
Antithrombin 2.5% 1.1%
Protein C 5.2% 2.2%
Protein S 3.1% 1.1%
Factor V Leiden 12.4% 5.2%
Prothrombin 
G20210A
21.5% 1.3%
Table 24: Etiology of Budd Chiari syndrome – Hereditary prothrombotic risk factors
Characteristics Janssen et al193 P Deltenre et al194 Present study
No. of patients 43 63 20
Antithrombin 0 0 25
Protein C 9.3 19.0 10 %
Protein S 0 6.7 0
Factor V Leiden 25.6 31.7 13.3 %
Prothrombin 
G20210A
4.7 6.4 0
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SUMMARY
1. 266  patients  with  documented  deep  vein  thrombosis  were  evaluated  for 
thrombophilia risk factors. 
2. Median age of presentation is 38 years (4-74) and only 4/266 (1.5%) were below 
15 years of age.
3. History  of  recurrence  and  family  history  was  present  in  38/266  (14.3%)  and 
10/266 (3.8%) of patients, respectively.
4. Male: Female ratio was 1:1.1 (140/126) for the whole group. Males were more 
commonly affected than females in the subgroups also, except for patients with 
cortical sinus thrombosis, where male: female ratio was 0.6:1. 
5. The  presenting  features  were  lower  limb  deep  vein  thrombosis  in  123/266 
(46.2%)  patients,  followed  by  cortical  sinus  thrombosis  in  92/266  (34.6%), 
pulmonary embolism in 26/266 (9.8%) and Budd Chiari syndrome was seen in 
20/266 (7.5%) of patients.
6. 121/266  (45.5%)  of  patients  were  on  anticoagulant  therapy  at  the  time  of 
evaluation.
7. Prothrombotic risk factors were present in 163/266 (61.3%) of patients and no 
risk factors were identified in 103/266 (38.7%) of patients. 
8. More than one risk factor was seen in 104/266 (39.1%) of patients.
9. Most common risk factor identified in these patients was an elevated factor VIII 
level- seen in 159/266 (59.7%) of patients.
10. Factor  V  Leiden  mutation  was  seen  in  16/203  (7.9%)  patients,  Prothrombin 
G20210A  mutation  in  2/203  (1.0%)  and  MTHFR  Cys677Thr  homozygous 
mutations in 7/203 (3.4%) of patients evaluated for these parameters. In patients 
with Budd Chiari syndrome the prevalence of Factor V Leiden mutation was 2/15 
(13.3%).
11. Protein C, S and antithrombin deficiency was present in 7/266 (2.6%), 13/266 
(4.8%) and 20/266 (7.5%) respectively.
76
12. Acquired risk factors were seen in 55/266 (20.7%) patients. Common acquired 
risk factors included lupus anticoagulant in 21/266 (7.9%), post partum state in 
12/266 (4.5%) and malignancies in 10/266 (3.7%) patients.
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CONCLUSIONS
Among patients  with  venous  thromboembolism,  proximal  lower  limb  veins  are  most 
commonly involved.  At  least  one prothrombotic  risk factor  is  identified  in  61.3% of 
patients.  The  commonest  risk  factor  identified  is  elevated  factor  VIII  level.  Other 
hereditary  risk  factors  for  thrombosis,  which  includes  factor  V  Leiden  mutation, 
Prothrombin G20210A mutation and MTHFR Cys677Thr homozygous mutation were 
seen but in less frequency than in the western population. Acquired causes were present 
in 20.7% of patients.
BIBLIOGRAPHY
1. White RH: The epidemiology of venous thromboembolism. Circulation 107:I-4-I-8, 2003
2. van Korlaar IM, Vossen CY, Rosendaal FR, Bovill EG, Cushman M, Naud S, et al: The impact of venous thrombosis on quality of life. Thromb Res 114:11-18, 
2004

3. Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, et al: Prospective evaluation of health-related quality of life in patients with deep venous 
thrombosis. Arch Intern Med 165:1173-1178, 2005
4. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al: Deep vein thrombosis and pulmonary embolism in two cohorts: The 
Longitudinal Investigation of Thromboembolism Etiology. Am J Med 117:19-25, 2004
5. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ: Predictors of survival after deep vein thrombosis and pulmonary embolism: A 
population-based cohort study. Arch Intern Med 159: 445-453, 1999
66. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978–981. 
78. McColl MD, Ellison J, Greer IA, et al. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol 
2000; 108: 272–274.
89. Bova C, Rossi V, Ricchio R, et al. Incidence of postthrombotic syndrome in patients with previous pulmonary embolism. A retrospective cohort study. Thromb 
Haemost 2004; 92: 993–996.
910. Gabriel F, Labios M, Portoles O, et al. Incidence of post-thrombotic syndrome and its association with various risk factors in a cohort of Spanish patients after 
one year of follow-up following acute deep venous thrombosis. Thromb Haemost 2004; 92: 328–336.
1011. Roumen-Klappe EM, den Heijer M, Janssen MC, et al. The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations 
in a six-year follow-up study. Thromb Haemost 2005; 94: 825–830.
1112. Wille-Jorgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A 
systematic review and meta-analysis. Thromb Haemost 2005; 93: 236–241.
1213. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 
2257–2264.
13 . Dahlbäck B. Blood coagulation. Lancet 2000; 355: 1627–1632.
14. Bombeli T, Mueller M, Haeberli A:  Anticoagulant properties of the vascular endothelium.   Thromb Haemost  1997; 77:408-423.
 
15. Marcus AJ, Broekman MJ, Drosopoulos JH, et al:  The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.   J Clin 
Invest  1997; 99:1351-1360.
16. Radomski MW, Palmer RM, Moncada S:  The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide.   Br J 
Pharmacol  1987; 92:639-646.
17. Zimmermann H:  Nucleotides and cd39: Principal modulatory players in hemostasis and thrombosis.   Nat Med  1999; 5:987-988.
18. Heeb MJ, Mesters RM, Tans G, et al:  Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.   
J Biol Chem  1993; 268:2872-2877.
19 . Goldhaber SZ: Pulmonary embolism. N Engl J Med 1998;339:93–104.
2020. heeler HB, Anderson FA Jr. Cardullo PA, Patwardhan NA, Li JM, Cutler BS. Suspected deep vein thrombosis: management by impedance 
plethysmography. Arch Surg 1982; 117:1206-09
21. Frederick A. Anderson, Jr., PhD, and Frederick A. Spencer, MD. Risk Factors for Venous Thromboembolism. Circulation. 2003;107:I-9 –I-16.
22. Rosendaal FR: Venous thrombosis: A multicausal disease. Lancet 353: 1167-1173, 1999
23. M Cushman: Epidemiology and risk factors for venous thrombosis. Semin Hematol 44:62-69
24 Saskia Middeldorp and Marcel Levi. Thrombophilia: An Update. Semin Thromb Hemost. 2007; 33(6):563-572
25. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988;208: 227–240.
26 . Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous 
heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318: 1162–1173.
27 . Gillinov AM, Davis EA, Alberg AJ, et al. Pulmonary embolism in the cardiac surgical patient. Ann Thorac Surg. 1992;53:988–991.
28 . Reis SE, Polak JF, Hirsch DR, et al. Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. Am Heart J. 
1991;122:478–482.
29. Clarke-Pearson DL, DeLong ER, Synan IS, et al. Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology 
patients and creation of a prognostic model. Obstet Gynecol.1987;69:146–150.
30 . Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970–1985. Am Heart J. 1987;114:1262–1264.
31 . Joffe SN. Incidence of postoperative deep vein thrombosis in neurosurgical patients. J Neurosurg. 1975;42:201–203.
32 . Stulberg BN, Insall JN, Williams GW, et al. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J 
Bone Joint Surg Am. 1984;66:194–201.
33 . White RH, Gettner S, Newman JM, Trauner KB, Romano P. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip 
arthroplasty. N Engl J Med 2000; 343: 1758–64.
34 . Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee 
replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465–71.
35 . Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med. 
2002;162:2173–2176.
36 . Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001:119(Suppl 1):132S–175S.
37 . Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann  Intern Med.1990;113:571–
574.
38 . Green D, Lee MY, Ito VY, et al. Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA. 1988; 260:1255–1258.
39 . Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients: a trial of anticoagulant prophylaxis with phenindione in 
middle aged and elderly patients with fractured necks or femurs. Lancet. 1959;1959:981–989.
40 . Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. 
N Engl J Med 2002; 347: 726–30.
41 . Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P: Cancer and venous thromboembolism. Semin Thromb Hemost  32:694-699, 2006. 
42. Sorensen HT, Mellemkjaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J 
Med 1998;338:1169–1173.
43. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J  Med 2000; 343:1846–1850.
44. Bauer KA: Venous thromboembolism in malignancy. J Clin Oncol 2000;18:3065.
45. Prandoni P, Lensing AWA, Buller HR, et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128–1133.
46. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. 
Blood. 2001;98:1614–1615.
47. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344: 1951–1952.
48. Clahsen PC, van de Velde CJH, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a 
European Organization for Research and Treatment of Cancer/Breast Cancer Cooperative Group Study. J Clin Oncol. 1994; 12:1266–1271.
49. Ali Seddighzadeh, Ranjith Shetty, Samuel Z. Goldhaber. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656–661
50.  Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9: 207–216.
51.  Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low 
molecular weight heparin (Fragmin).Thromb Haemost 1996; 75: 251–253.
52 . Cunningham MS, White B, Hollywood D, et al. Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence. 
Br J Cancer 2006; 94: 189–194.
53 . Anderson AJ, Krasnow SH, Boyer MW, et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989; 95: 71–75.
54 . Prandoni P, Lensing A, Cogo A, Cuppini S, Villalta S, Carta M, et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7, 
1996
55 . Prandoni P, Lensing A, Cogo A, Cuppini S, Villalta S, Carta M, et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7, 
1996
56 . McRae S, Tran H, Schulman S, Ginsberg J, Kearon C: Effect of patient’s sex on risk of recurrent venous thromboembolism: A meta-analysis. Lancet 368:371-
378, 2006
57 . Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al: Three months versus one year of oral  anticoagulant therapy for idiopathic deep 
venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345:165-169, 2001
58. Samama MM. Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice: the SIRIUS study. Thromb Haemost. 
1993;69:763.
59. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical 
patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800.
60. Kleber FX, Flosbach CW, Koppenhagen K. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in  the prevention of 
venous thromboembolic events in patients with heart failure NYHA III/IV (PRINCE II study). Circulation. 1999;100(Suppl 1):1–619.
61. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131–34.
62. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women 
with inherited clotting defects. Arch Intern Med 2000; 160: 49–52.
63 Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371–80.
64 Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198–202.
65 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in  oral contraceptive users who are 
carriers of factor V Leiden mutation. Lancet 1994; 344: 1453–57.
66 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in 
deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700–03.
67 Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452–63.
68 Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983–
987.
69 Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348: 977–980.
70. Lowe G, Woodward M, Vessey M, et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years. Relationships to 
hormone replacement therapy. Thromb Haemost. 2000; 83:530–535.
71 Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the 
randomized, double-blind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET). Thromb Haemost. 2000;84: 961–967.
72 . Baker WF, Bick RL. Antiphospholipid antibodies in coronary artery disease. Semin Thromb Hemost 1994;20:27 –45.
73 . Bell WR, Boss GR, Wolfson JS. Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med 1977;137:1471 – 3.
74 . Rodger L. Bick. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin N Am 17 (2003) 115– 147
75 . Bick RL, Baker WF. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 1992;6:1287–300.
76 . Bick RL, Baker WF. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 1994;20:3–15.
77 . Cariou R, Tobelem G, Bellucci S. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin-dependent 
protein C activation. Thromb Haemost 1988;60:54– 8.
78 . Carreras L, Defreyn G, Manchin S. Arterial thrombosis, intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacyclin 
formation. Lancet 1981; 1:244–6.
79 . McBane RDN, Panneton JM, Bate WW:  Aortic thrombosis as a complication of paroxysmal nocturnal hemoglobinuria.   Circulation  2001; 104:E1.
80 . Solovey A, Lin Y, Browne P, et al:  Circulating activated endothelial cells in sickle cell anemia.   N Engl J Med  1997; 337:1584.
81 . Eldor A, Rachmilewitz EA:  The hypercoagulable state in thalassemia.   Blood  2002; 99:36.
82 . Duran CANATAN, Muzaffer ZORLU, Neval BAYIR. Thrombosis After Splenectomy in Patients with Thalassemia. Turk J Haematol 2001;18(4):259-263.
83 . Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516. Abstract.
84 . Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370–1373.
85 . Comp P, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med. 1984;311:1525–1528.
86 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to 
activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–1008. Abstract.
87 . Poort SR, Rosendaal FR, Reitsma, et al. A common genetic variation in the 3_-untranslated region of the prothrombin gene is associated with elevated 
plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703.
88 . Mannucci PM: Laboratory detection of inherited thrombophilia: A historical perspective. Semin Thromb Hemost 31:5-10, 2005
89 . Crowther MA, Kelton JG: Congenital thrombophilic states associated with venous thrombosis: A qualitative overview and proposed classification system. Ann 
Intern Med 138:128-134, 2003
90 . Hultin MB, Jesty J. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood 1981;57:476– 82.
91 . Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001;86:75 – 82.
92 . Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258–64.
93 . Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact 
intrinsic pathway of coagulation. Thromb Haemost 1998;80:829– 35. 
94 . Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001;86:75 – 82.
95 . Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86:66– 74.
96 . Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin- thrombomodulin complex. Nature 2000;404:518– 
25.
97 Charles T. Esmon. The Protein C Pathway. Chest 2003;124;26-32
98
 . Fay PJ. Factor VIII structure and function. Thromb Haemost 1993;70:63– 7.
99 . Bick RL. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C and protein S defects. Hematol Oncol Clin North Am 2003;17:9.
100 . Reitsma PH, Bernardi F, Doig RG, et al:  Protein C deficiency: A database of mutations, 1995 update.   Thromb Haemost  1995; 73:876.
101 . Bovill EG, Bauer KA, Dickerman JD, et al:  The clinical spectrum of heterozygous protein C deficiency in a large New England kindred.   Blood  1989; 73:712.
102 . Broekmans AW, Veltkamp JJ, Bertina RM:  Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families.   N Engl J 
Med  1983; 309:340.
103 . Wintzen AR, Broekmans AW, Bertina RM, et al:  Cerebral hemorrhagic infarction in young patients with hereditary protein C deficiency: Evidence for 
"spontaneous" cerebral venous thrombosis.   BMJ  1985; 290:350.
104 . Heijboer H, Brandjes DPM, Büller HR, et al:  Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep venous thrombosis.   N 
Engl J Med  1990; 323:1512.
105 . Koster T, Rosendaal FR, Briët E, et al:  Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous 
thrombosis (Leiden Thrombophilia Study).   Blood  1995; 85:2756.
106 . Mateo J, Oliver A, Borrell M, et al:  Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism
—results of the Spanish multicentric study on thrombophilia (EMET Study).   Thromb Haemost  1997; 77:444.
107 . Gladson CL, Scharrer I, Hach V, et al:  The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated patients with venous 
thrombosis.   Thromb Haemost  1988; 59:18.
108 . Ben-Tal O, Zivelin A, Seligsohn U:  The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel.   Thromb 
Haemost  1989; 61:50.
109 . Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994;87(1):106–112
110 . Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb
Haemost 1995;73(1):87–93
111 . Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor 
VaR506Q by activated protein. J Biol Chem 1995;270:21158–66.
112 . Schwarz HP, Fischer M, Hopmeier P, et al:  Plasma protein S deficiency in familial thrombotic disease.   Blood  1984; 64:1297.
113 . Martinelli I, Mannucci PM, DeStefano V, et al:  Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 
families.   Blood  1998; 92:2353.
114 Faioni EM, Valsecchi C, Palla A, et al:  Free protein S deficiency is a risk factor for venous thrombosis.   Thromb Haemost  1997; 78:1343.
115 . Makris M, Leach M, Beauchamp NJ, et al:  Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of 
protein S.   Blood  2000; 95:1935.
116
 . Engesser L, Broekmans AW, Briet E, et al:  Hereditary protein S deficiency: Clinical manifestations.   Ann Intern Med  1987; 106:677.
117 . Broekmans AW, Bertina RM, Reinalda-Poot J, et al:  Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families.   
Thromb Haemost  1985; 53:273.
118
 . Comp PC, Doray D, Patton D, Esmon CT:  An abnormal plasma distribution of protein S occurs in functional protein S deficiency.   Blood  1986; 67:504.
119 . Gandrille S, Borgel D, Sala N, et al:  Protein S deficiency: A database of mutations-summary of the first update.   Thromb Haemost  2000; 84:918.
120 . Dahlbäck B:  Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system.   Thromb 
Haemost  1991; 66:49.
121. Ulrich Abildgaard. Antithrombin – Early prophecies and present challenges. Thromb Haemost 2007; 98: 97–104
122 . Carrell R, Skinner R, Abrahams JP:  Structural mobility of antithrombin and its modulation by heparin.   Thromb Haemost  1997; 78:516-519.
123 . Ambruso DR, Leonard BD, Bies RD, et al:  Antithrombin III deficiency: Decreased synthesis of a biochemically normal molecule.   Blood  1982; 60:78.
124 . Lane DA, Bayston T, Olds RJ, et al:  Antithrombin mutation database: 2nd (1997) update.   Thromb Haemost  1997; 77:197.
125 . Tait RC, Walker ID, Perry DJ, et al:  Prevalence of antithrombin deficiency in the healthy population.   Br J Haematol  1994; 87:106.
126 . Thaler E, Lechner K:  Antithrombin III deficiency and thromboembolism.   Clin Haematol  1981; 10:369. (abstract)
127 . van der Meer FJM, Koster T, Vandenbroucke JP, et al:  The Leiden Thrombophilia Study (LETS).   Thromb Haemost  1997; 78:631.
128 . Kane WH, DavieEW. Blood coagulation factors Vand VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. 
Blood 1988;71:539– 55.
129 . Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor 
VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996;76:208–14.
130 . Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII [letter]. Thromb Haemost 
1995;73:730– 1.
131 . Monkovic D, Tracy P. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990;29:1118– 28.
132 . Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII [letter]. Thromb Haemost 
1995;73:730– 1.
133 . Svensson PJ, Dahlbäck B:  Resistance to activated protein C as a basis for venous thrombosis.   N Engl J Med  1994; 330:517.
134
 . Griffin JH, Evatt B, Wideman C, Fernandez JA:  Anticoagulant protein C pathway defective in majority of thrombophilic patients.   Blood  1993; 82:1989.
135 . Faioni EM, Franchi F, Asti D, et al:  Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay.   Thromb 
Haemost  1993; 70:1067.
136 . van der Meer FJM, Koster T, Vandenbroucke JP, et al:  The Leiden Thrombophilia Study (LETS).   Thromb Haemost  1997; 78:631.
137 . Bertina RM, Koeleman BPC, Koster T, et al:  Mutation in blood coagulation factor V associated with resistance to activated protein C.   Nature  1994; 369:64.
138 . Sun X, Evatt B, Griffin JH:  Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.   
Blood  1994; 83:3120.
139 . Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH:  High-risk of thrombosis in patients homozygous for factor V Leiden (APC-resistance).   
Blood  1995; 85:1504.
140 . Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167– 73.
141 . Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001;86:395–403.
142 . Preston FE, Rosendaal FR, Walker ID, et al:  Increased fetal loss in women with heritable thrombophilia.   Lancet  1996; 348:913.
143 . Martinelli I, Taioli E, Cetin I, et al:  Mutations in coagulation factors in women with unexplained late fetal loss.   N Engl J Med  2000; 343:1015.
144 . Kupferminc MJ, Eldor A, Steinman N, et al:  Increased frequency of genetic thrombophilia in women with complications of pregnancy.   N Engl J 
Med  1999; 340:9.
145 . Rees DC, Cox M, Clegg JB:  World distribution of factor V Leiden.   Lancet  1995; 346:1133.
146 . Williamson D, Brown K, Luddington R, et al:  Factor V Cambridge: A new mutation (Arg306➙Thr) associated with resistance to activated protein C.   
Blood  1998; 91:1140.
147 . Chan WP, Lee CK, Kwong YL, et al:  A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.   Blood  1998; 91:1135.
148 . Poort SR, Rosendaal FR, Reitsma PH, Bertina RM:  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with 
elevated prothrombin levels and an increase in venous thrombosis.   Blood  1996; 88:3698.
149 . Pollak ES, Lam H, Russell JE:  The G20210A mutation does not affect the stability of prothrombin mRNA in vivo.   Blood  2002; 100:359.
150 . Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3’-
untranslated region of the Prothrombin gene. Br J Haematol 1997;98:907– 9.
151 . Ray Lee,, Eugene P. Frenkel. Hyperhomocysteinemia and thrombosis. Hematol Oncol Clin N Am 17 (2003) 85– 102
152 . Hessner MJ, Luhm RA, Pearson SL, et al. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase 
(MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999;81:733–8.
153 . Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat 
Genet 1995;10:111 –3.
154 . Pepe G, Rickards O, Vanegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997;77:329– 31.
155 . Hessner MJ, Luhm RA, Pearson SL, et al. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase 
(MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999;81:733–8.
156 . Zheng YZ, Tong J, Do XP, et al. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the 
Chinese population. Br J Haematol 2000;109:870–4.
157 . Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma 
homocysteine concentrations. Circulation 1996;93:7– 9.
158 . R. Lee, E.P. Frenkel. Hyperhomocysteinemia and thrombosis. Hematol Oncol Clin N Am 17 (2003) 85–102.
159 . Starkebaum G, Harlan JM:  Endothelial cell injury due to copper-catalyzed hydrogen peroxide from homocysteine.   J Clin Invest  1986; 77:1370.
160 . Wang J, Dudman NPB, Wilken DEL:  Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial 
cells.   Thromb Haemost  1993; 70:1047.
161 . Rodgers GM, Conn MT:  Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells.   Blood  1990; 75:895.
162 . Fermo I, D'Angelo SV, Paroni R, et al:  Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.   
Ann Intern Med  1995; 123:747.
163 . Den Heijer M, Blom HJ, Gerrits WBJ, et al:  Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?.   Lancet  1995; 345:882.
164 . Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein 
thrombosis. Lancet 345:152-155, 1995
165 . Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al: High plasma concentration of factor VIIIc is a major risk 
factor for venous thromboembolism. Thromb Haemost 83:5-9, 2000
166 . Lensen R, Bertina RM, Vandenbroucke JP, Rosendaal FR: High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J 
Haematol 114:380-386, 2001
167 . O’Donnell J, Mumford AD, Manning RA, Laffan M: Elevation of FVIII: C in venous thromboembolism is persistent and  independent of the acute phase 
response. Thromb Haemost 83:10-13, 2000
168 . De Visser MCH, van Hylckama Vlieg A, Tans G, Rosing J, Dahm AE, Sandset PM, et al: Determinants of the APTT- and ETP-based APC sensitivity tests. J 
Thromb Haemost 3:1488-1494, 2005
169 . O’Donnell J, Mumford AD, Manning RA, Laffan MA: Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. 
Br J Haematol 115:687-691, 2001
170 . van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR: High levels of factor IX increase the risk of venous  thrombosis. Blood 95:3678-3682, 
2000
171
 . Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E: Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 
years. Relationships to hormone replacement therapy. Thromb Haemost 83:530-535, 2000
172 . Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, et al: The risk of recurrent venous  thromboembolism among patients with 
high factor IX levels. J Thromb Haemost 1:28-32, 2003
173 . Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP: Factor VII and fibrinogen levels as risk factors for venous thrombosis. 
A case-control study of plasma levels and DNA polymorphisms—The Leiden Thrombophilia Study (LETS). Thromb Haemost 71:719-722, 1994
174 . van Hylckama Vlieg A, Rosendaal FR: High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb 
Haemost 1:2677-2678, 2003.
175 . Mossesson MW:  Dysfibrinogenemia and thrombosis.   Semin Thromb Hemost  1999; 25:311.
176 . Haverkate F, Koopman J, Kluft C, et al:  Fibrinogen Milano II: A congenital dysfibrinogenemia associated with juvenile arterial and venous thrombosis.   
Thromb Haemost  1986; 55:131.
177 Kraaijenhagen RA, Anker P S, Koopman MM et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Throm 
Haemost 2000; 83: 5-9.
178 Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.  
179  K. Ghosh, Venous Thromboembolism in Young Patients from Western India: A Study, Clinical and Applied Thrombosis/Hemostasis, Vol. 7,  
No. 2, 158-165 (2001)
180. Maurizio Margaglione,Vincenzo Brancaccio,Domenico De Lucia et al, Inherited Thrombophilic Risk Factors and Venous Thromboembolism. Distinct Role in 
Peripheral Deep Venous Thrombosis and Pulmonary Embolism. CHEST 2000; 118:1405–1411
181 . Armando Tripodi, Veena C, Ida martinelli et al. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. 
Blood. 2004;104:3631-3634.
182 . Daniela Tormene, Sabrina Gavasso, Valeria Rossetto et al. Thrombosis and thrombophilia in children. Semin Thromb Hemost 2006; 32:724-728.
183. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452–63.
184 . Hron G, Eichinger S, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al: Family history for venous thromboembolism and the risk for recurrence. Am J 
Med 119:50-53, 2006
185. Frederick A. Anderson, Jr., Frederick A. Spencer, Risk Factors for Venous Thromboembolism, Circulation. 2003; 107: I-9 –I-16.
186 . José M. Ferro, Patrícia Canhão, Jan Stam et al. Prognosis of Cerebral Vein and Dural Sinus Thrombosis. Results of the International Study on Cerebral Vein 
and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
187 . Francesco Dentali, Mark Crowther, and Walter Ageno. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-
analysis. Blood. 2006; 107:2766-2773.
188 . S F T M de Bruijn, R J de Haan, J Stam. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. J 
Neurol Neurosurg Psychiatry 2001;70:105–108.
189 . Harry L. A. Janssen, Johan R. Meinardi, Frank P. Vleggaar et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation 
inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364-2368.
190 . P Deltenre, M-H Denninger, S Hillaire et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48:264–268
191 .  Ida Martinelli, Tullia Battaglioli, Paola Pedotti et al, Hyperhomocystinemia in cerebral vein thrombosis. Blood 2003;102:1363-1366.
192 Robert H. Thomas. Hypercoagulability Syndromes. Arch Intern Med. 2001;161:2433-2439. 
193 de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous 
thrombosis. J Thromb Haemost 2005;3:1993-7.
194 . O'Donnell J, Tuddenham EG, Manning R. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased 
synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997 May;77(5):825-8.
